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Reproductive function in the dog is controlled by feedback mechanisms that 
involve the hypothalamus, the anterior pituitary gland, and the gonads. Surgical gonad 
removal, a common procedure performed in dogs for the purposes of sterilization, 
disrupts the hypothalamic-pituitary-gonadal (HPG) axis and results in permanently 
elevated concentrations of gonadotropins. Manipulation of the HPG axis via 
gonadotropin releasing hormone (GnRH) immunization results in the synthesis of GnRH 
neutralizing antibodies, which bind to (neutralize) GnRH and prevent it from binding to 
its receptors. The end result of GnRH immunization is the cessation of pituitary 
gonadotropin secretion, namely luteinizing hormone (LH).  
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In 2004, a commercial GnRH vaccine was launched in the United States (Canine 
Gonadotropin Releasing Factor Immunotherapeutic
®; Pfizer Animal Health USA),  
labeled for the treatment of benign prostatic hyperplasia in intact male dogs. This 
research investigated two novel clinical applications of this vaccine in dogs.  
In the first study, physiologic responses to GnRH immunization in intact male 
dogs were observed. Four intact males were vaccinated with the GnRH vaccine twice at 
four week intervals. Blood samples were collected prior to each injection (at weeks 0 and 
4) and at weeks 12 and 20 following initial vaccination. Scrotal measurements were also 
made at the time of each blood sample collection to calculate testicular volume. All four 
dogs developed a GnRH antibody titer and experienced a significant decrease in 
testosterone concentrations.  Testicular volume also significantly decreased, and this 
effect was reversed by the end of the study. LH concentrations remained at basal levels. 
These results are indicative of temporary humoral response to the GnRH vaccine, and 
future studies should investigate prolonging these effects to potentiate GnRH 
immunization as a method of population control in dogs. 
Beyond use as a temporary immunosterilant, GnRH immunization has other 
promising clinical applications. Elevated gonadotropin concentrations as a result of 
gonad removal in female dogs decreases urethral pressure, and in some bitches, this 
results in the development of urethral sphincter mechanism incompetence (USMI). 
Therefore, lowering gonadotropin concentrations in incontinent ovariectomized bitches 
through GnRH immunization may restore continence. In the second study, sixteen 
incontinent dogs that were using phenylpropanolamine (PPA) to control incontinence  
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were recruited. Eleven dogs were immunized against GnRH at week 0, and nine dogs 
were vaccinated again four weeks later. Five control dogs were vaccinated with a placebo 
twice at four week intervals. Vaccinated dogs discontinued PPA two weeks after re-
vaccination, and control dogs remained on PPA for the duration of the study. Blood 
samples were collected before each injection and at 6, 8, 10, 12, 16, 20, and 24 weeks, 
and owners recorded episodes of incontinence throughout the study. Of the nine dogs that 
completed the vaccination series, four dogs remained continent after PPA was 
discontinued. For these four dogs, there was no difference in the episodes of incontinence 
when using PPA versus treatment with the vaccine. All nine vaccinated dogs developed a 
GnRH antibody titer, and LH concentrations decreased significantly in vaccinated dogs 
compared to controls.  These results indicate that decreasing LH concentrations through 
GnRH immunization restores continence to some, but not all incontinent ovariectomized 
bitches. Because the development of USMI results from decreased urethral pressure that 
happens after ovariectomy, future studies should focus on preventing this decrease in 
urethral pressure to prevent USMI from occurring. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS IN THE BITCH 
 
1.1.1 Summary 
 
Gonadotropin and steroid hormone secretion in the dog is primarily controlled by 
feedback mechanisms that involve the hypothalamus, the anterior pituitary gland, and the 
gonads (Fink, 1988).  Gonadectomy, a surgical technique performed frequently in 
veterinary practice as a reliable means of population control, disrupts the hypothalamic-
pituitary-gonadal (HPG) axis (Stockner, 1991). For the purposes of this review, only the 
implications of gonad removal in the female dog (ovariectomy) will be discussed. 
 
1.1.2 Gonadotropin-Releasing Hormone  
 
  Gonadotropin-releasing hormone (GnRH) is a decapeptide (pGlu
1-His
2-Trp
3-Ser
4-
Tyr
5-Gly
6-Leu
7-Arg
8-Pro
9-Gly
10-NH2)  synthesized and stored in GnRH neurons located 
in the medial basal and  preoptic area of the hypothalamus (Jeong and Kaiser, 2006). 
There have been three isoforms of GnRH recognized in animals; mammalian GnRH-I, 
chicken GnRH-II, and lamprey GnRH-III  (Khan et al., 2007). However, GnRH-I is 
accepted as the main fertility-regulating peptide (Khan et al., 2007) and will be the only 2 
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isoform discussed for the purposes of this review. Release of GnRH is controlled by 
steroidal hormone feedback as well as non-steroidal hormones, such as melatonin, 
catecholamines, and opiods (Fink, 1988).  Under neuronal stimulation, GnRH is released 
in a pulsatile manner and moves through nerve terminals in the median eminence (Jeong 
and Kaiser, 2006). These terminals are in close proximity to the primary capillary bed of 
the hypophyseal portal system (Clarke and Pompolo, 2005), allowing GnRH to enter 
circulation and access its receptors on gonadotrophs in the anterior pituitary. GnRH has a 
high specificity to its receptor (GnRHR) in the anterior pituitary (Clarke and Pompolo, 
2005), and GnRHR regulation is dependent on GnRH itself (Katt et al., 1985).  
 
1.1.3 Gonadotropins 
 
  The gonadotropins luteinizing hormone (LH) and follicle stimulating hormone 
(FSH) are located in the pars distalis region of the anterior pituitary. Both gonadotropins 
are glycoproteins composed of an α and β subunit (Childs, 2006). The α subunit is 
common to both LH and FSH, while the β subunit is distinct and determines hormonal 
specificity (Jeong and Kaiser, 2006). 
  In the female, LH stimulates androgen production in ovarian theca cells, which is 
converted into estradiol in the ovarian granulosa cells with the assistance of FSH 
(Palermo, 2007). FSH is responsible for promoting initial ovarian follicle development 
from primary to antral follicles; only FSH receptors are expressed in the granulosa cells 
at these stages (Palermo, 2007). FSH then induces the expression of LH receptors in the 3 
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granulosa cells of mature follicles, allowing the follicle to become increasingly 
responsive to LH (Palermo, 2007). As a result, LH is the gonadotropin responsible for 
dominant follicle selection, subsequent ovulation, and luteinization of the dominant 
follicle (Childs, 2006; Palermo, 2007).  
LH and FSH are both secreted by the same pituitary cell type, the gonadotrophs, 
but they are both differentially regulated (Crawford and McNeilly, 2002; de Gier et al., 
2006). Gonadotropin secretion is modulated by hypothalamic feedback; GnRHR-ligand 
binding causes the rapid mobilization of intracellular calcium  (Ca
2+), and this triggers the 
exocytosis of LH and FSH (Farnworth, 1995; Jeong and Kaiser, 2006). Frequent GnRH 
pulses with low amplitude support LH synthesis and secretion, while less frequent GnRH 
pulses with high amplitude support FSH synthesis and secretion (Palermo, 2007).   
Gonadotropin secretion is modulated by gonadal feedback as well. It is thought that this 
mechanism is also partially responsible for the differential secretion of LH and FSH 
because gonadectomy results in a concurrent rise in both FSH and LH, thereby reducing  
differential secretion (Shupnik, 1996).  
 
1.1.4 Gonadal Feedback 
 
  The two reproductive steroid hormones produced by the ovary, estrogen and 
progesterone, also contribute to HPG axis modulation. Progesterone, produced by the 
luteal cells of the corpus luteum, is the steroid hormone that dominates the luteal phase 
(Messinis, 2006). When circulating concentrations are elevated, progesterone negatively 4 
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feeds back directly on the median basal hypothalamus, decreasing GnRH pulse frequency 
and consequently LH secretion. Progesterone also acts on gonadotrophs in the anterior 
pituitary to decrease LH secretion directly, but this mechanism is estrogen-dependent 
(Girmus and Wise, 1992).  By decreasing GnRH pulse frequency and LH secretion, 
progesterone allows for the maintenance of the corpus luteum. 
  Estradiol, the estrogen that dominates during the nonpregnant reproductive cycle, 
has both a negative and positive feedback role. During follicular development, estradiol 
concentrations increase as the follicle grows and negatively feeds back on both the 
hypothalamus and anterior pituitary to reduce the amplitude of GnRH and LH secretion, 
allowing LH to build up in the gonadotrophs (Palermo, 2007). During the late follicular 
phase, estradiol concentrations are postulated to reach a threshold, which signals a change 
that results in estradiol positively feeding back on the hypothalamus and pituitary 
(Clarke, 1995). This increases GnRH secretion, which causes an LH surge. The LH 
surge, coupled with an increased responsiveness of the dominant follicle to LH, results in 
ovulation. 
  In addition to reproductive steroid hormones, the ovary also secretes the peptides 
inhibin, activin, and follistatin, whose biological effects act specifically upon FSH 
(Shupnik, 1996).  Inhibin is produced by the granulosa cells of antral follicles and 
suppresses FSH release (Shupnik, 1996). Increased inhibin concentrations occur as the 
dominant follicle emerges and therefore results in a decline in FSH (Findlay, 1993). 
Another gonadal peptide, activin, is also produced by granulosa cells, and it stimulates 
FSH production (Findlay, 1993; Shupnik, 1996). It is mainly secreted by preantral 5 
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follicles, which contributes to their responsiveness to FSH (Findlay, 1993). However, 
precisely how activin signaling integrates into the network of other hormonal signaling 
pathways has yet to be elucidated (Coss et al., 2010). Finally, The granulosa cells are also 
the major site of production for the gonadal peptide follistatin (Findlay, 1993). While 
follistatin does not directly affect FSH, it does bind to and therefore inhibit activin action, 
therefore indirectly affecting FSH production (Shupnik, 1996).  Given that gonadal 
peptide action is exerted on FSH only and not LH, these peptides are postulated to 
contribute to the differential secretion of the gonadotropins (Shupnik, 1996). 
   
1.1.5 HPG Axis in the Intact Bitch 
 
  The canine estrous cycle is comprised of anestrus, proestrus, estrus, and diestrus. 
Late anestrus is characterized by the inititation of folliculogenesis, which results from an 
increase in LH and FSH pulsatility (Kooistra et al., 1999; Olson et al., 1982). During 
proestrus, follicles continue to develop in response to FSH and produce increasing levels 
of estradiol, which stimulates increased pulse frequency of GnRH. This accumulates in a 
preovulatory gonadotropin surge, resulting in a 1-3 day elevation in LH and a 1-4 day 
elevation of FSH (Concannon, 2011).  The LH surge occurs near the onset of estrus, 
which lasts 1-3 days in the bitch (Concannon, 2011).  Ovulation then occurs 48-60 hours 
following the onset of the LH surge (Concannon, 2011). Progesterone, originating from 
the developing corpora lutea, steadily increases during estrus and the first half of diestrus, 
then plateaus and declines during the remainder of diestrus. Elevated progesterone 6 
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negatively feeds back on LH, and concentrations remain low yet dynamic during diestrus, 
indicative of pulsatile secretion (Kooistra et al., 1999).  
 
1.1.6 HPG Axis in the Ovariectomized Bitch 
 
  Ovary removal results in the inability for gonadal steroid hormones to feed back 
upon the hypothalamus and anterior pituitary, and this results in a rapid increase in LH 
and FSH concentrations. This effect is seen across mammalian species, including women 
(Yen and Tsai, 1971). In the bitch, LH and FSH concentrations stabilize approximately 
one year post-surgery at 7 and 14-fold increases, respectively (Reichler et al., 2004). 
Gonadotropin elevations remain permanently elevated; however, concentrations remain 
somewhat dynamic, reflective of pulsatility still occurring (Concannon, 1993).  
  There are potential negative effects of ovariectomy that vary between species.  
For example, the dog is predisposed to urinary incontinence (Reichler, 2009); the  ferret 
is predisposed to hyperadrenocorticism (Schoemaker et al., 2002); the rodent and rabbit 
are at increased risk for osteoporosis (Rosen et al., 2000; Sevil and Kara, 2010; Yamazaki 
and Yamaguchi, 1989); and the woman is at an increased risk for cardiovascular 
problems, cognitive impairment, and osteoporosis (Shuster et al., 2008).  These effects 
could be due to gonadotropin elevation, which may be impacting specific tissues through 
extragonadal receptor-ligand binding; extragondal gonadotropin receptors have been 
identified in various locations in different species. 
 7 
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1.2 NONCLASSICAL ACTIONS OF GNRH, LH, AND FSH IN THE BITCH 
 
1.2.1 Summary 
 
  The expression of GnRH and gonadotropin receptors have been identified in 
numerous extragonadal tissues that vary among species, indicating that these hormones 
may exhibit actions beyond the HPG axis. Extragonadal receptors for GnRH and LH 
have been identified most extensively in the rodent and human (Pakarainen et al., 2007; 
Skinner et al., 2009), but there is less documentation available on extragonadal FSH 
receptors (Mizrachi and Shemesh, 1999).  Extragonadal GnRH, LH, and FSH receptors 
identified in various female species are summarized in Table 1.1. In the dog, GnRH and 
gonadotropin receptors have been identified in the skin (Welle et al., 2006), urinary 
bladder (Coit et al., 2009; Ponglowhapan et al., 2007; Reichler et al., 2007), and urethra 
(Ponglowhapan et al., 2007; Reichler et al., 2007). While the presence of these receptors 
has been identified, the role of GnRH and gonadotropins in extragonadal tissue is still 
unclear. 
 
1.2.2 Action on the Skin 
 
  Immunohistochemical studies have shown that GnRH, FSH, and LH receptors are 
present in canine skin, specifically the epidermis, infundibulum, isthmus, sebaceous 
glands, sweat glands, and the arrector pili muscles (Welle et al., 2006). Some bitches    
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Table 1.1.  Extragonadal GnRH, LH, and FSH receptor expression in various species. 
Female 
Species  Extragonadal GnRHR  Extragonadal LHR  Extragonadal FSHR  References 
Dog 
Bladder  
Skin  
Urethra 
Bladder  
Skin  
Urethra 
Bladder  
Skin  
Urethra 
(Coit et al., 2009; Ponglowhapan et al., 2007; 
Reichler et al., 2007; Welle et al., 2006) 
Human 
Adrenal gland 
Bladder 
Heart 
Kidney 
Liver 
Skeletal muscle 
Adrenal gland 
Bladder 
Uterine blood vessels 
Cervix 
Oviduct 
Skin  
Uterus 
Not reported  (Pakarainen et al., 2007; Skinner et al., 2009) 
Rat 
Adrenal gland 
Brain 
Eye 
Kidney 
Liver 
Skeletal muscle 
Skin 
Adrenal gland 
Brain 
Kidney 
Mammary gland 
Spinal cord 
Uterus 
Not reported  (Fields and Shemesh, 2004; Pakarainen et al., 2007; 
Skinner et al., 2009) 
Mouse 
Bladder 
Brain 
Eye 
Heart 
Kidney 
Liver 
Skin 
Oviduct 
Uterus   Not reported  (Pakarainen et al., 2007; Skinner et al., 2009) 
Sheep 
Brain 
Eye 
Spinal cord 
Uterus  Not reported  (Fields and Shemesh, 2004; Skinner et al., 2009) 
Cow  Adrenal gland 
Oviduct 
Uterus 
Uterine blood vessels 
 Cervix  (Fields and Shemesh, 2004; Mizrachi and Shemesh, 
1999; Skinner et al., 2009) 9 
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display a change in coat quality after ovariectomy, collectively referred to as 'puppy coat 
syndome' (Fontaine and Fontbonne, 2011). Affected dogs have an increase in wool hair 
and a decrease in color intensity, and this is undesirable to dog owners (Reichler et al., 
2008). This coat difference can be attributed to a significant increase in the 
anagen:telogen ratio, or the hair follicle growth:resting ratio, in dogs one year after 
ovariectomy (Reichler et al., 2008). However, the incidence of this coat change post-
ovariectomy is approximately 20%, so the pathophysiological mechanism underlying the 
change between elevated gonadotropins and change in coat quality still needs to be 
elucidated (Reichler et al., 2008).  
 
1.2.3 Action on the Urinary Bladder and Urethra 
 
  Receptors for GnRH (Reichler et al., 2007), LH (Ponglowhapan et al., 2007; 
Reichler et al., 2007), and FSH (Ponglowhapan et al., 2007) are present in the canine 
bladder and urethra. Urinary incontinence as a consequence of ovariectomy is a common 
problem in  bitches, and the incidence of post-spay incontinence is reported to be 
between 5.7-20%  while the incidence of incontinence in intact females is between 0-1% 
(Arnold et al., 1992; Thrusfield et al., 1998). Urinary incontinence in both intact and 
neutered male dogs is also uncommon (Aaron et al., 1996). Therefore, there may be an 
effect of reproductive status and gender on the expression of LH and FSH receptors. 
Ponglowhapan and co-workers (2008) found significantly less receptor expression in 
ovariectomized females compared to intact females, but there was no difference between 10 
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intact and neutered males. This is in contrast to Reichler and colleagues (2007), who 
found no overall difference in LH or GnRH receptor expression between intact and 
ovariectomized females. It is important to mention though that the dogs used in the 
Ponglowhapan study were all in anestrus, while the dogs used in the Reichler study were 
at different stages of the cycle. The stage of the estrous cycle could affect gonadotropin 
receptor expression and therefore result in variability between individuals; it has been 
demonstrated in the human female that maximum LH receptor expression in the uterus, 
an extragonadal tissue, occurs during the luteal phase (Shemesh, 2001). 
In contrast to both these studies, Coit and coworkers (2009) found a significant 
increase in LH and GnRH receptor expression in gonadectomized female and male dogs 
compared to intact. Receptor expression for LH was also found to be significantly greater 
in intact females compared to intact males. The authors attributed these conflicting 
findings to the population of dogs observed. For example, Ponglowhapan and colleagues 
studied dogs that had been gonadectomized less than one year prior, and it is possible that 
changes in receptor expression continue longer than one year following gonadectomy 
(Coit et al., 2009), especially considering LH and FSH concentrations in gonadectomized 
dogs do not stabilize until approximately 42 weeks post-gonadectomy (Reichler et al., 
2004).  
   
1.2.4 Conclusions 
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  It is accepted that in the dog, LH, FSH, and GnRH receptors are present in the 
extragonadal tissues of the skin, bladder, and urethra. However, additional research is 
needed to determine other extragonadal tissues that may be responsive to these hormones 
and what the conclusive effects of gonadecomy are on LH, FSH, and GnRH receptor 
expression. 
 
1.3 APPLICATIONS OF GNRH ANALOGUES AND IMMUNIZATION 
 
1.3.1 Summary 
 
  Given that the GnRH sequence pGlu
1-His
2-Trp
3-Ser
4-Tyr
5-Gly
6-Leu
7-Arg
8-Pro
9-
Gly
10-NH2 is conserved across all mammals, developing GnRH analogues with the goal 
of manipulating fertility in various species has been an ongoing area of research. GnRH 
analogues (agonists and antagonists) and immunization have all been utilized in the dog 
because of the strong need for antifertility agents (Junaidi et al., 2003). Future work with 
these compounds includes increasing the duration of effect for long-term methods of non-
surgical sterilization. 
 
1.3.2 GnRH Agonists 
 
  Development of agonists has focused on producing sequences with a high affinity 
for GnRH receptors and increased resistance to degradation or elimination, allowing for a 12 
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product more potent than GnRH itself (Padula, 2005). Areas of manipulation of the 
GnRH sequence for agonist development primarily target the end of the amino acid chain 
(replacing Gly
10-NH2), the beginning of the chain (replacing pGlu
1), and the center of the 
chain (replacing Gly
6). Furthermore, replacing the L-isomer Gly
6 with a D-isomer has  
been shown to drastically increase overall potency of the agonist (Padula, 2005). 
Depending upon binding affinity, the rate of dissociation, and duration of use, 
GnRH agonists can either stimulate or inhibit the production and release of gonadotropins 
from the pituitary. Initial administration results in an immediate increase in gonadotropin 
concentrations, referred to as the flare-up effect (Gobello, 2007). This short-term flare-up 
lasts days to weeks and is followed by a desensitization and therefore inhibition of 
gonadotropin secretion that is reversible when the GnRH agonist is discontinued (Conn 
and Crowley, 1991). While gonadotropin suppression is ultimately achieved for long 
durations of time, the initial flare-up can be problematic if the agonist is being used in an 
anti-fertility application. 
  GnRH agonists have been widely investigated in the dog for both reproductive 
and non-reproductive applications. Short-term administration of GnRH agonists (during 
the flare-up period) results in estrous induction (Fontaine et al., 2011; Inaba et al., 1998; 
Volkmann et al., 2006), while long-term administration has been investigated for various 
clinical applications. GnRH agonists that have been investigated in the dog are 
summarized in Table 1.2.   
To date, deslorelin is the only product that has been developed specifically for 
long-term fertility control in domestic animals (Herbert and Trigg, 2005). Its modified  
 
                               
13  
Table 1.2. GnRH agonists and antagonists investigated in the dog. 
Common Name  Type   Clinical Applications  Reference 
Acyline  Antagonist 
Testicular characteristic alterations  
Testosterone suppression 
Pregnancy termination 
Estrous cycle interruption 
(García Romero et al., 2012; 
Valiente et al., 2007, 2009a, 2009b) 
Cetrorelix  Antagonist  Testosterone  suppression  (Schwahn et al., 2000) 
Deslorelin  Agonist 
Delay of puberty 
Induction of fertile estrus 
Estrous synchronization 
Antifertility agent 
Treatment for benign prostatic hyperplasia 
Treatment for urinary incontinence 
Reversal of spay-induced coat changes 
(Fontaine et al., 2011; Junaidi et al., 
2003, 2009; Limmanont et al., 
2011; Reichler et al., 2003, 2008; 
Romagnoli et al., 2009; 
Sirivaidyapong et al., 2012; 
Volkmann et al., 2006) 
Leuprolide  Agonist 
Induction of fertile estrus 
Gonadotropin suppression 
Suppression of testicular function 
Effect on bladder and urethral function 
Treatment for urinary incontinence 
(Inaba et al., 1996, 1998; Reichler 
et al., 2006a, 2006b) 
Nafarelin  Agonist 
Suppression of spermatogenesis 
Recrudescence of spermatogenesis after 
treatment cessation  
Suppression of estrus 
Treatment for benign prostatic hyperplasia 
(Goericke-Pesch et al., 2009, 2010; 
Ludwig et al., 2009; McRae et al., 
1985; Paramo et al., 1993) 
Buserelin  Agonist  Estrus induction 
Treatment for urinary incontinence 
(Reichler et al., 2003; Rota et al., 
2003) 
Goserelin  Agonist  Treatment of hormone-dependent mammary 
tumors  (Lombardi et al., 1999) 14 
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sequence is a D-isomer of Trp substituting for Gly
6 as well as Pro
9-ethylamide 
substituting for Gly
10-NH2 (Padula, 2005). In the dog, long-term administration results in 
delayed puberty and acts as an anti-fertility agent in both males and females (Junaidi et 
al., 2003, 2009; Romagnoli et al., 2009). Deslorelin is also effective in treating benign 
prostatic hyperplasia by lowering testosterone concentrations (Limmanont et al., 2011). 
Furthermore, because elevated gonadotropin concentrations result from ovariectomy, 
deslorelin has been investigated as a treatment for urinary incontinence and puppy coat 
syndrome in ovariectomized female dogs (Reichler et al., 2003, 2008).  
  Leuprolide is another GnRH agonist that has been investigated in the dog (Herbert 
and Trigg, 2005). Its modified sequence is a D-isomer of Leu substituting for Gly
6 as 
well as Pro
9-ethylamide substituting for Gly
10-NH2 (Padula, 2005). This agonist 
suppresses testicular function and gonadotropin concentrations with long-term 
applications (Inaba et al., 1996; Reichler et al., 2006a). Leuprolide was also found to 
restore urinary continence completely in 9 out of 22 incontinent ovariectomized bitches 
(Reichler et al., 2006b). While urethral closure pressure and function did not change in 
ovariectomized continent Beagles treated with leuprolide, bladder threshold volume 
significantly increased (Reichler et al., 2006a).  
 
1.3.3 GnRH Antagonists 
 
GnRH antagonists compete with GnRH for receptor occupancy and cause an 
immediate suppression of gonadotropin secretion (van Loenen et al., 2002). Development 15 
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of antagonists have focused on producing sequences with a high affinity for the GnRH 
receptor but no actual activation of the receptor, and this has been achieved by 
manipulating approximately 5-7 amino acid positions in the GnRH sequence (Herbst, 
2003; Padula, 2005). However, a major limitation of GnRH antagonist application has 
been the difficulty in synthesizing long-term release formulations without side effects 
(Gobello, 2012). Depot preparations currently available require monthly administration 
(Agersø et al., 2003; Broqua et al., 2002; Klotz et al., 2008). While limited data is 
available concerning the use of GnRH antagonists in domestic carnivores (Gobello, 
2012), GnRH antagonists have promising clinical reproductive applications. Antagonists 
investigated to date in the dog are summarized in Table 1.2. 
Acyline, a third-generation antagonist, has substitutions in 7 amino acid positions 
with a sequence of Ac-D-2Nal
1-D-4Cpa
2-D-3Pal
3-Ser
4-4Aph(Ac)
5-D-4Aph(Ac)
6-Leu
7-
ILys
8-Pro
9-D-Ala
10-NH2 (Valiente et al., 2007). It has demonstrated the ability to 
interrupt proestrus and block ovulation as well as safely terminate mid-pregnancy by 
suppressing progesterone concentrations in female dogs (Valiente et al., 2009a, 2009b). 
In male dogs, acyline has been investigated as an immunosterilant and decreases 
testosterone concentrations for approximately 14 days (García Romero et al., 2012) and 
furthermore impairs sperm concentration and motility for approximately six weeks 
(Valiente et al., 2007). Cetrorelix, another third-generation antagonist, has substitutions at 
5 amino acid positions with a sequence of Ac-D-2Nal
1-D-4Cpa
2-D-3Pal
3-Ser
4-Tyr
5-D-
Cit
6-Leu
7-Arg
8-Pro
9- D-Ala
10-NH2 (Padula, 2005). It  suppresses testosterone 16 
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concentrations in dogs, but the effect is short-lived; dogs returned to normal testosterone 
levels by 48 hours after initial injection (Schwahn et al., 2000). 
 
1.3.4 Immunization against GnRH 
 
  Another method for suppressing gonadotropin secretion is through active 
immunization against GnRH. Because native GnRH has a short biological half-life and 
low immunogenicity, effectively immunizing against GnRH requires GnRH or an 
analogue to be conjugated with an antigenic carrier molecule (usually an inactivated 
bacteria or virus) and then combined with an adjuvant to increase the immunoreactivity 
(Cox and Coulter, 1997; Fürst et al., 1994). When an animal is immunized with a GnRH 
vaccine, GnRH neutralizing antibodies are synthesized, which prevent GnRH from 
binding to its receptors in the anterior pituitary and consequently blocks the synthesis of 
gonadotropins and therefore steroid hormones (Fürst et al., 1994) (Figure 1.1).  
Two commercially produced and several privately produced GnRH vaccines have 
been tested in dogs.  GonaCon™ (United States Department of Agriculture, Fort Collins, 
CO) has been developed for wildlife population control, and it has been investigated in 
squirrels, swine, wild horses, white-tailed deer, cats, dogs, and other species (Alliance for 
Contraception in Cats and Dogs, 2009).  While preliminary research using this vaccine as 
an immunosterilant in male dogs resulted in severe adverse injection site reactions 
(Alliance for Contraception in Cats and Dogs, 2009), reproductive inhibition did last one 
year in treated dogs (Miller et al., 2004). However, another study investigating the effect 17 
 
 
19
 
 
              
 
 
Figure 1.1. Mechanism of action of gonadotropin releasing hormone (GnRH) 
immunization. Before immunization (left), GnRH is secreted by the hypothalamus, where 
it binds to its receptors on the anterior pituitary and elicits the secretion of luteinizing 
hormone (LH) and follicle stimulating hormone (FSH). After immunization (right), 
antibodies form against GnRH (GnRH-ab), preventing receptor binding and therefore 
halting LH and FSH secretion. Key of symbols provided at bottom. 
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of GonaCon™ on rabies virus antibody production demonstrated no adverse effects of 
Gonacon™ when administered to female dogs (Bender et al., 2009). 
The other commercial GnRH vaccine, Canine Gonadotropin Releasing Factor 
Immunotherapeutic
® (Pfizer Animal Health, Exton, PA) (package insert shown in Figure 
1.2),  is specifically labeled for use in dogs. This vaccine was produced for the treatment 
of benign prostatic hyperplasia in intact male dogs with a recommendation of 
revaccination every 6 months (Pfizer Animal Health). However, it is also effective in 
temporarily decreasing testosterone concentrations and testicular volume in healthy intact 
male dogs (Donovan et al., 2012) and for pregnancy termination in bitches (Chew and 
Purswell, 2010), suggesting the vaccine may be effective as a reversible immunosterilant.  
  Finally, GnRH immunization has demonstrated anti-fertility effects in various 
non-commercial vaccine compositions as well (Jung et al., 2005; Ladd et al., 1994; 
Walker et al., 2007).  The different vaccine compositions and applications of GnRH 
immunization in the dog are summarized in Table 1.3. 
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Figure 1.2. Canine Gonadotropin Releasing Factor Immunotherapeutic® package insert. Outside cover (left) and inside leaves 
(right). 
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Table 1.3. GnRH immunization products investigated in the dog. 
Common Name  Vaccine Composition  Clinical Applications  Reference 
GonaCon™ 
GnRH peptide conjugated to 
keyhole limpet hemocyanin with 
AdjuVac™ adjuvant 
Immunosterilization 
(Alliance for Contraception in 
Cats and Dogs, 2009; Bender 
et al., 2009; Miller et al., 2004) 
Canine Gonadotropin 
Releasing Factor 
Immunotherapeutic
® 
GnRH peptide conjugated to 
diptheria toxoid with a 
proprietary plant-based adjuvant 
Pregnancy termination 
Decreasing testosterone and testicular 
volume 
Treatment for benign prostatic hyperplasia 
(Chew and Purswell, 2010; 
Donovan et al., 2012; Hashimi 
et al., 2008; Pfizer Animal 
Health; Russo, 2008) 
Non-commercial 
formulation 
GnRH peptide conjugated to T 
helper cell epitope (originating 
from canine distemper virus and 
goat rotavirus) with Iscomatrix
® 
adjuvant 
Immunosterilization  (Jung et al., 2005) 
Non-commercial 
formulation 
GnRH peptide conjugated to 
tetanus toxoid with MDP A-5 
adjuvant 
Immunosterilization  (Ladd et al., 1994) 
Non-commercial 
formulation 
GnRH peptide conjugated to T 
helper cell epitope (originating 
from canine distemper virus) 
with Iscomatrix
® adjuvant 
Immunosterilization   (Walker et al., 2007) 
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1.4 ETIOPATHOPHYSIOLOGY OF URINARY INCONTINENCE IN THE BITCH 
 
1.4.1 Summary 
 
Urinary incontinence is the involuntary release of urine (Moore, 2001).  Resting 
urethral closure pressure and continence largely depend on the tonic sympathetic 
noradrenergic activation of α-1 adrenoreceptors on urethral smooth muscle (Brune et al., 
2001). Ovariectomy causes a deterioration of urethral closure pressure (Reichler et al., 
2004), and urethral sphincter mechanism incompetence (USMI)  post-ovariectomy 
remains the most prevalent cause of canine incontinence (Holt, 1985). However, other 
causes of urinary incontinence exist and can be categorized into congenital anatomic 
abnormalities, neurologic disorders, or functional disorders. 
 
1.4.2 Congenital Anatomic Abnormalities 
 
  Anatomic abnormalities that can result in urinary incontinence include ectopic 
ureters, congenital sphincter mechanism incompetence, bladder hypoplasia, and 
vestibulo-vaginal stenosis.  Ectopic ureter is an abnormality where one or both ureters 
terminate distal to the neck of the bladder instead of  in the bladder, allowing urine to 
bypass the urethral sphincter and therefore leak freely without being contained 
(Lautzenhiser and Bjorling, 2002). Surgical correction repositions the ureter(s) into the 
bladder to restore continence (Holt, 1983).  Congenital sphincter mechanism incontinence 22 
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usually occurs as a result of a short and/or wide urethra, resulting in the urinary sphincter 
being inadequate (Holt, 1983). Bladder hypoplasia is the underdevelopment of the 
bladder, which results in a low capacity and incontinence. Finally, many dogs with 
vestibulo-vaginal stenosis, or abnormal narrowing of the caudal vagina, display 
incontinence because urine can pool cranial to the stenosis (where the urethra opens into 
the vagina) and susbsequently dribble out. However, continent dogs can also have 
vestibulo-vaginal stenosis and therefore, it cannot be considered a cause for incontinence 
but rather a complicating factor (Holt, 1983). 
 
1.4.3 Neurologic Disorders 
 
  Neurologic disorders that result in urinary incontinence can be divided into two 
subtypes: flaccid neurogenic bladder and spastic neurogenic bladder. Flaccid neurogenic 
bladder is a lower motor neuron dysfunction that results in an excessively dilated bladder 
and an inability to contract, resulting in a retention of urine and overflow incontinence 
(Ponglowhapan et al., 2012). Spastic neuropathic bladder is a upper motor neuron 
dysfunction where incomplete voiding of the bladder occurs (Ponglowhapan et al., 2012). 
A type of spastic bladder, reflex dyssynergia, is characterized by normal initiation of 
bladder voiding, followed by a decrease and  then a sudden interruption in flow 
(Espiñeira et al., 1998). Treatment aims to re-coordinate bladder voiding with urethral 
relaxation (Espiñeira et al., 1998). 
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1.4.4 Functional Disorders 
 
  The most common cause of urinary incontinence is acquired urinary sphincter 
mechanism incompetence (USMI) as a result of ovariectomy (Holt, 1985).  Gonadectomy 
is associated with urethral functional modifications that may contribute the development 
of USMI (Noël et al., 2010). In the dog, it has been demonstrated that mean urethral 
closure pressure is significantly reduced after ovariectomy (Arnold, 1997; Reichler et al., 
2004) and is further reduced in incontinent dogs (Richter and Ling, 1985). Specifically, 
Arnold and colleagues (1997) reported that a urethral closure pressure of less than 7.4 cm 
H2O allowed for the differentiation of bitches with urinary incontinence with a diagnostic 
accuracy of 91%. However, the definite underlying mechanism(s) of incontinence 
resulting from reduced urethral closure pressure has not been concretely determined 
(Reichler et al., 2006a). It has been hypothesized that elevated gonadotropins as a result 
of ovariectomy may affect urethral pressure, but when incontinent dogs were treated with 
GnRH agonists to reduce gonadotropin concentrations,  there was no change in urethral 
pressure even in cases of restored continence (Reichler et al., 2006b).  
The development of USMI is most likely multifactorial due to multiple 
predisposing factors. However, it is well evidenced that ovariectomy is the primary 
predisposing factor for urinary incontinence. The incidence of incontinence has been 
reported from 5.7-20% (Arnold et al., 1992; Holt and Thrusfield, 1993) in ovariectomized 
bitches whereas the incidence of incontinence in intact bitches is 0-1% (Holt and 
Thrusfield, 1993). Gender is also a major predisposing factor. Females are far more 24 
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affected than males; one study reported 235/244 (96.3%) of adult patients diagnosed with 
USMI were female (Holt, 1990a). It is also well established that medium and large dogs 
are also more likely to develop incontinence than small dogs (Angioletti et al., 2004; 
Chew and DiBartola, 2007; Holt and Thrusfield, 1993). Other potential predisposing 
factors include obesity; Angioletti and coworkers (2004) found that bitches that were 
overweight before ovariectomy had 3.5 times more risk of developing incontinence 
compared to non-obese bitches. Tail docking has also been suggested as a risk factor for 
urinary incontinence as many breeds with a high predisposition for developing 
incontinence (Boxers, Rottweilers, Dobermans, Old English Sheepdog) have docked tails 
(Holt and Thrusfield, 1993; Ponglowhapan et al., 2012). However, no studies have 
compared docked and undocked dogs of the same breed, so it is currently unknown if the 
incidence of incontinence is related to size, tail docking, or both in these breeds.  
Estrogen deficiency has been hypothesized as a cause for urinary incontinence 
(Arnold et al., 2009) and was originally supported by the fact that approximately 65% of 
incontinent bitches treated with estrogens have returned to continence (Janszen et al., 
1997). However, the permanent elevation of gonadotropins as a result of ovariectomy has 
also been hypothesized to be a cause for urinary incontinence, especially considering LH 
and FSH extragonadal receptors are present in the canine lower urinary tract (Coit et al., 
2009; Ponglowhapan et al., 2007; Reichler et al., 2007).  Estrogen therapy restores the 
disrupted HPG axis and therefore decreases elevated gonadotropins, so this would 
explain why estrogen can be an effective treatment for incontinence. Furthermore, long-
acting GnRH depot agonists have been evaluated for the treatment of incontinence, and 25 
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treatment success was comparable to estrogen therapy (Reichler et al., 2003, 2006b). This 
is further evidence that gonadotropin excess, not estrogen deficiency, is what may cause 
urinary incontinence.  
 
1.4.5 Conclusions 
 
The major endocrinological change resulting from ovariectomy (e.g. elevated 
gonadotropins) has an effect on the pathophysiology of urinary incontinence. Elevated 
gonadotropins bombarding their receptors in the urinary tract may be what induces the 
decrease in urethral pressure, and this effect seems to be non-reversible as reducing 
gonadotropin concentrations in ovariectomized continent and incontinent dogs did not 
increase urethral closure pressure (Reichler et al., 2006a, 2006b). However, treating 
incontinent dogs with GnRH agonists to effectively decrease gonadotropin concentrations 
restored continence in some dogs (Reichler et al., 2003, 2006b), indicating that urinary 
incontinence is dependent on circulating gonadotropin levels in some cases. However, it 
is possible that over time, the effects of elevated gonadotropins may not be fixable by 
only decreasing gonadotropin concentrations. This is further evidenced incontinent dogs 
that are treated successfully with combinations of GnRH agonists or estrogen therapy 
with phenylpropanolamine when one treatment alone was not effective. Further 
information regarding incontinence treatment will be discussed in the next section.  
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1.5 CURRENT METHODS FOR THE TREATMENT OF URINARY SPHINCTER 
MECHANISM INCOMPETENCE (USMI) IN THE BITCH 
 
1.5.1 Summary 
 
  Various treatment regimens have been investigated to treat acquired urinary 
sphincter mechanism incompetence (USMI), both surgical and  non-surgical. Medical 
therapy is the first line of treatment for most affected dogs, but surgical treatment may be 
pursued if medical management has failed, side effects develop, or if owners are reluctant 
to medicate long term (Claeys et al., 2010; McLoughlin and Chew, 2009). Numerous 
treatment approaches exist for both categories. 
 
1.5.2 Surgical Treatment Options 
   
  The overall goal of surgical treatment of USMI is to increase urethral resistance to 
the outflow of urine (McLoughlin and Chew, 2009). To date, surgical procedures to treat 
USMI in the dog have been adapted from procedures performed on women with urinary 
incontinence (Claeys et al., 2010; McLoughlin and Chew, 2009). Less popular surgical 
options for the treatment of USMI in the dog include urethral slings, artificial sphincters, 
and urethral lengthening. Due to increased invasiveness and/or lack of efficacy, these 
procedures are not commonly recommended. 27 
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  Colposuspension is the most commonly performed surgical treatment for USMI in 
the dog (McLoughlin and Chew, 2009). Briefly, sutures are placed between the prepubic 
tendon and seromuscular layer of the vagina, and this relocates the bladder neck and 
proximal urethra to a more cranial position, exposing both structures to intra-abdominal 
pressure and therefore adding pressure onto the bladder neck (Claeys et al., 2010; 
McLoughlin and Chew, 2009; Rawlings et al., 2001). Colposuspension has been 
demonstrated to successfully restore continence initially in approximately 50% of cases 
(Holt, 1990b; Rawlings et al., 2001). However, efficacy of the procedure long-term is not 
as successful; Rawlings and coworkers (2001) reported that only 3 of 22 bitches that 
underwent colposuspension were still continent twelve months after surgery compared to 
12 out of 22 bitches that were continent two months after surgery. As a result, many dogs 
that undergo colposuspension will need additional medical therapy to have the best 
urinary control possible (Rawlings, 2002). 
  Urethropexy is another surgical procedure to treat USMI. Briefly, sutures are 
placed between the body wall and the seromuscular layer of the urethra (McLoughlin and 
Chew, 2009).  This procedure is similar to colposuspension in that the bladder neck is 
relocated to a more cranial position and is therefore more susceptible to intra-abdominal 
pressure. However, it is also speculated that additional urethral resistance is created by 
causing a urethral kink at the level of the urethropexy (White, 2001). The success of 
urethropexy to restore continence initially is similar to colposuspension. White (2001) 
reported approximately 56% success with a worsening of response to the procedure over 
time.  28 
 
 
 
20
 
  Urethral bulking is a minimally invasive procedure designed to increase urethral 
resistance. Briefly, a needle is guided endoscopically to just below the mucosal layer of 
the urethra, and a substance is then injected  in 3-4 sites around the submucosal layer of 
the urethra (McLoughlin and Chew, 2009). While Teflon was the substance formerly 
used for this procedure, rejection of the foreign matter that resulted in a return to 
incontinence made the material unfavorable for use (Barth et al., 2005). Therefore, 
collagen is the preferred agent for urethral bulking due to a higher degree of 
biocompatibility (McLoughlin and Chew, 2009). Studies have demonstrated 
approximately 53-68% success in restoring continence using collagen implantation, but 
continence deteriorates over time (Arnold et al., 1996; Barth et al., 2005). Collagen 
flattening over time may be what leads to an eventual return to incontinence (Claeys et 
al., 2010).  
    
1.5.3 Non-Surgical Treatment Options 
   
  Numerous medical therapies exist for the treatment of USMI through direct or 
indirect action on urethral musculature. This form of management is non-invasive and 
therefore the first option considered by many pet owners when treating USMI. 
  Phenylpropanolamine (PPA) is a synthetic adrenergic agonist that mimics the 
effects of endogenous catecholamines. PPA stimulates the sympathetic nervous system 
by activating α1 adrenoreceptors that are expressed in vascular smooth muscle cells, 
resulting in vasoconstriction (Flavahan, 2005). Urethral closure pressure is naturally 29 
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maintained by activation of α1 adrenoreceptors of the urethral smooth musculature in the 
dog by the sympathetic nervous system  (Hashimoto et al., 1992), and therefore, PPA is 
effective when urethral closure pressure is not sufficient to maintain continence because 
it helps stimulate α1 adrenoreceptor activation. Currently, PPA is the most common 
therapy for treating USMI and is effective in 75-85% of cases (Arnold et al., 2009; Scott 
et al., 2002). PPA is FDA approved for use in dogs to treat urinary incontinence and is 
marketed in the United States under the trade name Proin
® (PRN Pharmacal, Pensacola, 
FL). 
  While PPA is the most effective treatment for USMI currently available, it can 
produce side effects that makes the drug less appealing to some dog owners. PPA is not 
selective for the α1 adrenoreceptors within the urinary tract (Yakoot, 2012) and as a 
result, vasoconstriction of smooth musculature can occur in a variety of tissues. Side 
effects of PPA include hypertension, weight loss, emesis, proteinuria, anorexia, lethargy, 
and behavior changes (Pegasus Laboratories Inc., 2011). Furthermore, PPA's short half-
life of approximately 4 hours (Hussain et al., 1987) requires frequent administration of 
the drug to maintain therapeutically effective vasoconstriction. In addition, drug 
treatment must be maintained for the dog's lifetime. 
  Ephedrine and pseudoephedrine are α-adenergic agonists that have also 
successfully treated USMI. However, in addition to stimulated α1-adenergic receptors 
like PPA, ephedrine and pseudoephedrine also stimulate β1, 2, and 3 receptors, resulting 
in an increase in side effects (Arnold et al., 2009; Byron et al., 2007; Vansal and Feller, 
1999).  30 
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  Estrogen therapy increases urethral closure pressure by increasing receptor 
sensitivity to catecholamines and has been used to treat USMI (Larsson et al., 1984). 
Estrogen therapy also decreases circulating concentrations of luteinizing hormone and 
follicle stimulating hormone (Chew and DiBartola, 2007), which are permanently 
elevated as a result of ovariectomy and may contribute to the development of urinary  
incontinence (Reichler et al., 2003). In the United States, there are two estrogens 
currently used in dogs. Diethylstilbestrol (DES) is a synthetic estrogen available from 
compounding pharmacies, and estriol is a natural estrogenic compound that is FDA 
approved under the trade name Incurin
® (Merck Animal Health, Summit, NJ). While 
DES and estriol both rapidly associate with estrogen receptors, estriol has a fast rate of 
dissociation while DES forms a stable complex and therefore dissociates more slowly 
(Rich et al., 2002). The canine bone marrow is exquisitely sensitive to the suppressing 
effects of estrogens. As a result, bone marrow suppression is a potential adverse effect of 
estrogen treatment, and therefore, the shorter-acting and less potent estriol is preferred 
over longer-acting estrogen forms (Arnold et al., 2009; Sondern and Sealey, 1940). 
Estrogen therapy for the treatment of USMI is 50-65% effective (Janszen et al., 1997; 
Mandigers and Nell, 2001; Nendick and Clark, 1987). Side effects include signs of estrus, 
attractiveness to male dogs, and swelling of the vulva and teats. However, decreasing the 
dose can prevent or reduce side effects in some cases (Mandigers and Nell, 2001). 
Reducing the dosing frequency with DES (administering a few times a week instead of 
daily) may reduce side effects in some cases. Estriol must be given daily to have an 
effect. 31 
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  GnRH agonists have recently been investigated as a potential treatment for USMI. 
They decrease LH and FSH concentrations through downregulation of GnRH receptors in 
the anterior pituitary, and  this mechanism of action has been hypothesized to restore 
continence  to incontinent bitches. Treatment with GnRH agonists restores continence in 
approximately 50% of bitches (Reichler et al., 2003, 2006b), comparable to estrogen 
therapy. However, GnRH agonist treatment lasts significantly longer than other medical 
treatments available, ranging from 50-738 days after agonist administration with no 
adverse effects (Reichler et al., 2003, 2006b).  
 
1.5.4 Combination Therapy with PPA 
 
  Successful combination  therapies with PPA have been reported when the initial 
surgical or non-surgical treatment is not effective alone. Administering PPA after a 
surgical procedure to treat USMI can fully restore continence (Barth et al., 2005; Holt, 
1990b; Rawlings, 2002). Administering PPA with estrogens (Arnold et al., 2009; Chew 
and DiBartola, 2007) or GnRH agonists (Reichler et al., 2003) is effective in treating 
USMI when any treatment alone is not efficacious. 
 
1.5.5 Conclusions 
 
  Various surgical and non-surgical options exist for the treatment of urinary 
incontinence and combining any of these therapies may restore continence when one 32 
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treatment method individually is not efficacious. However, no single treatment is 
completely effective in treating urinary incontinence. This has stimulated  further 
research interest into the underlying pathophysiology of USMI with the aim of 
developing more effective treatments without side effects (Ponglowhapan et al., 2012). 
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2.1 ABSTRACT 
 
We investigated the use of a commercial gonadotropin-releasing hormone 
(GnRH) vaccine as a method of temporary and reversible immunocastration in intact 
male dogs. Four privately-owned dogs were vaccinated twice at four week intervals. 
Blood samples were collected at 0, 4, 12, and 20 weeks following the initial vaccination. 
These samples were analysed for GnRH antibody titres, luteinizing hormone (LH) and 
testosterone concentrations. Scrotal measurements were made at the time of sample 
collection, and testicular volume was calculated using the formula of an ellipsoid. As a 
result of vaccination, dogs displayed an elevated GnRH antibody titre, decreased LH and 
testosterone concentrations and decreased testicular volume, which reversed by the end of 
the study period. Therefore, these results suggest that immunizing against GnRH may be 
a possible choice for temporary and reversible immunocastration. 
 
2.2 INTRODUCTION 
 
Nonsurgical sterilization methods are highly desirable for domestic animals for 
population control purposes as well as for animals that are not candidates for surgery. 
The hypothalamic-pituitary-gonadal axis, which is the regulator of mammalian 
reproductive function, has specifically been a target of manipulation for 
immunocontraception development. Briefly, gonadotropin releasing hormone (GnRH), a 44 
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trophic decapeptide secreted from the hypothalamus, controls the release of follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. In 
turn, LH and FSH act upon the testes in the male to stimulate testosterone production, 
which then negatively feeds back on the hypothalamus and anterior pituitary to regulate 
GnRH secretion. By diminishing GnRH production, the production of LH, FSH and 
testosterone are diminished as well. 
It has been shown previously in intact male dogs that vaccinating with a GnRH 
analogue effectively decreases testosterone concentration (Sabeur et al., 2005; Walker et 
al., 2007). A commercially manufactured GnRH vaccine in the United States (Canine 
Gonadotropin Releasing Factor Immunotherapeutic
®; Pfizer Animal Health, Exton, PA, 
USA; referred to in this manuscript as a 'commercial canine GnRH vaccine'), labelled for 
the twice-annual management of benign prostatic hyperplasia in intact male dogs, may 
also be an ideal option for a reversible means of immunocastration. The vaccine elicits 
antibodies that bind to GnRH and render it nonfunctional, ultimately decreasing testicular 
testosterone production (Pfizer Animal Health, Package Insert). 
The objective of this study was to measure endocrine responses in intact male 
dogs after administering a commercial canine GnRH vaccine. Furthermore, because 
testosterone production is necessary for spermatogenesis and testicular volume largely 
reflects spermatogenesis (Gouletsou et al., 2008), testicular volume measurements were 
also recorded. It was expected that immunization against GnRH would temporarily elicit 45 
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a GnRH antibody titre, decrease LH and testosterone concentrations and decrease 
testicular volume in intact males. 
 
2.3 MATERIALS AND METHODS 
 
2.3.1 Animals, Vaccination, Sample Collection, and Scrotal Measurements 
Four privately-owned intact male dogs were used for this study. Dogs were 
vaccinated subcutaneously with 1 ml of commercial canine GnRH vaccine twice at 4-
week intervals (at week 0 and 4). Animals were closely monitored for adverse reactions 
following each vaccination. Venous blood samples were collected prior to each 
vaccination (0 and 4 weeks) and at 12 and 20 weeks following initial treatment. Sera 
were separated, aliquoted, and frozen at -20°C until analysis.  
Scrotal length, width and height were measured using calipers at weeks 0, 4, 12, 
and 20. Testes were aligned side by side and forced down into the scrotum as far as 
possible for each measurement. This is the standard method for testis measurement in 
dogs and causes no observable pain to the animal. Measurements were used to calculate 
testicular volume using the formula of an ellipsoid, length × width × height × 0.5236, as 
described by Gouletsou et al. (2008). 
2.3.2 Hormone Assays 46 
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  Gonadotropin-releasing hormone antibody titres were determined by enzyme-
linked immunosorbent assay (ELISA) using a technique modified from Elhay et al. 
(2007). Briefly, 96-well microtitre plates were coated with 100 µl of 5 µg/ml of LH-RH 
(71447-49-9, Sigma, St. Louis, MO, USA) in sodium bicarbonate buffer (pH 8.0) at 4ºC 
overnight.  After incubation, plates were washed with phosphate buffered saline 
containing 0.05% Tween-20 (TPBS) (pH 8.0) and were then blocked with a serum 
dilution buffer (phosphate buffered saline containing 0.5% bovine serum albumin, pH 
8.0). After 1-h incubation period at room temperature, plates were washed with TPBS 
and serum samples were diluted in the serum dilution buffer, yielding final serum 
dilutions ranging from 1:2 to 1:128. After washing with TPBS, antibodies were detected 
using horseradish peroxidase protein G conjugate (HRP) (10-1223, Invitrogen, Camarillo, 
CA, USA) diluted as 1:2000 in serum dilution buffer for 1 h at room temperature. After a 
final wash with TPBS, HRP was visualized with ABTS peroxidase substrate (50-66-01, 
KPL, Gaithersburg, MD, USA). Absorbances were read at 405 nm using a 
spectrophotometer (Bio-Tek Instruments Inc., Winooski, VT, USA). The antibody titre 
was expressed as an endpoint titre for each sample, which was calculated from a 
regression line of optical density against the sample dilution with a threshold of 0.200 
optical density using a software program (KinetiCalc, Bio-Tek Instruments Inc., 
Winooski, VT, USA).  
  Serum samples were analysed for LH concentrations using an ELISA kit for 
canine serum (LH-Detect
®, Repropharm, Nouzilly, France) and performed according to 
the manufacturer’s instructions. The limit of detection was 0.12 ng/ml, and all assays 47 
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were performed in duplicate. Serum samples were also analysed for testosterone at the 
Animal Health Diagnostic Center at Cornell University using Coat-A-Count
® Total 
Testosterone radioimmunoassay (Diagnostics Products Corporation, Los Angeles, CA, 
USA), validated for dogs by Reimers et al. (1991), and performed according to the 
manufacturer’s instructions. The detection limit of the assay was 0.04 ng/mL. The 
coefficients of variation for the intra-assay and inter-assay variability were 4-21% and 6-
27%, respectively, depending on the testosterone concentration. 
2.3.3 Statistical Analysis 
Gonadotropin-releasing hormone antibody titres, LH concentrations, and 
testosterone concentrations, and the per cent change in testicular volume were analysed 
as a repeated measure in time design using PROC MIXED in SAS (Version 9.2, SAS 
Institute Inc., Cary, NC, USA). Significance was defined as p≤0.05. LH concentrations 
are expressed as mean ± SEM and GnRH antibody titres, testosterone concentrations and 
per cent change in testicular volume are expressed as mean ± SD. 
 
2.4 RESULTS 
 
None of the dogs vaccinated experienced an adverse reaction to the vaccine and 
remained clinically healthy for the duration of the study. All dogs were seronegative for 
antibodies against GnRH prior to the first vaccination and were seropositive for 
antibodies against GnRH after receiving the first vaccination. Antibody titres peaked at 48 
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12 weeks post-vaccination and were significantly greater at week 12 compared to week 0 
(p<0.001), week 4 (p=0.008), and week 20 (p=0.01) (Fig. 2.1).  
  Luteinizing concentrations remained at basal levels (<0.8 ng/mL) post-
vaccination (Fig. 2.1). All  dogs also experienced a decrease in testosterone concentration 
following vaccination (Fig. 2.1). Concentrations of testosterone were below the detection 
limit of the assay at week 12, a significant decrease (p=0.02) compared to pre-vaccination 
testosterone levels. At week 20, there was a slight but insignificant rise in testosterone 
concentrations.   
 All dogs experienced a decrease in testicular volume following GnRH 
vaccination (Fig. 2.2). Testicular volume was significantly decreased at week 12 
compared to week 0 (p=0.05), week 4 (p=0.02), and week 20 (p=0.01). At week 20, there 
was a slight but insignificant rise in testicular volume, consistent with the increase in 
testosterone concentrations. 
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Figure 2.1. Serum GnRH-Ab titre (±SD; left axis) as compared to testosterone (±SD) and 
luteinizing hormone (±SEM) concentrations (ng/ml; right axis) at weeks 0, 4, 12, and 20 
following GnRH vaccination. 
ap<0.05 compared to GnRH-Ab titres at weeks 0, 4, and 
20. 
bp<0.05 compared to testosterone concentration at week 0 
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Figure 2.2. Change in testicular volume (%) at weeks 0, 4, 12, and 20 following GnRH 
vaccination. *p<0.05 compared to weeks 0, 4, and 20 
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2.5 DISCUSSION 
 
An alternative to surgical castration is needed for population control in dogs that 
are not surgical candidates because of health limitations and other reasons. A vaccine that 
elicits antibodies against GnRH to effectively decrease steroid hormone production is a 
potential option for a temporary, reversible means of immunosterilization. Although this 
commercial canine GnRH vaccine has been studied to treat benign prostatic hyperplasia 
in intact male dogs, it has not been thoroughly studied as an immunocontraceptive, and 
therefore, the objective of this study was to measure endocrine responses and testicular 
volume changes in intact male dogs as a result of vaccination. 
  As approximately 70-80% of testicular mass consists of seminiferous tubules 
(Gouletsou et al., 2008), measurement of testicular volume is largely reflective of the 
capacity for spermatogenesis. The dogs used in this study all responded to the vaccine by 
developing a GnRH antibody titre, and this resulted in a significant decrease in 
testosterone production and also a significant decrease in testicular volume. 
Luteinizing concentrations remained at basal levels (<0.8 ng/ml) in all dogs post-
vaccination, but this was not significant compared to week 0, perhaps because of the 
cyclical secretion pattern of LH. The time interval in between LH peaks in the intact male 
dog is approximately 103 min (Olson et al. 1992). Therefore, collecting multiple samples 
over a 2-h time interval is needed to determine if LH secretion was suppressed as a result 
of vaccination. This frequency of sampling was not feasible in the current study because 
the dogs used were privately owned. 52 
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In conclusion, vaccinating intact male dogs with a commercial canine GnRH 
vaccine induces a temporary and reversible humoral response that results in decreased 
testosterone concentration and decreased testicular volume. Further study using a double-
blind placebo-controlled format that also evaluates sexual behaviour, semen quality and 
repeated immunization is a necessary next step. 
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CHAPTER III 
 
 
GONADOTROPIN-RELEASING HORMONE IMMUNIZATION FOR THE 
TREATMENT OF URINARY SPHINCTER MECHANISM INCOMPETENCE IN 
OVARIECTOMIZED BITCHES 
 
3.1 ABSTRACT 
 
We have investigated gonadotropin-releasing hormone (GnRH) immunization for 
the treatment of urethral sphincter mechanism incompetence in ovariectomized bitches. It 
has been demonstrated that decreasing luteinizing hormone (LH) secretion through the 
use of GnRH depot agonists restores continence in some bitches. Therefore, decreasing 
circulating LH concentrations through immunization against GnRH may also maintain 
continence in incontinent dogs as well. Sixteen incontinent dogs that were using 
phenylpropanolamine (PPA) to control incontinence were recruited for this study. Eleven 
dogs were immunized against GnRH at week 0, and nine dogs were vaccinated again four 
weeks later. Five control dogs were vaccinated with a placebo twice at four week 
intervals. Vaccinated dogs discontinued PPA two weeks after re- vaccination, and control 
dogs remained on PPA for the duration of the study. Blood samples were collected before 
each injection and at 6, 8, 10, 12, 16, 20, and 24 weeks, and owners recorded episodes of 
incontinence throughout the study. Of the nine dogs that completed the vaccination 
series, four dogs remained continent after PPA was discontinued. For these four dogs, 
there was no difference in the episodes of incontinence when using PPA versus treatment 54 
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with the vaccine. All nine vaccinated dogs developed a GnRH antibody titer, and LH 
concentrations decreased significantly in vaccinated dogs compared to controls.  In 
conclusion, GnRH immunization was effective in maintaining continence in 44% of 
incontinent ovariectomized dogs, and in these dogs, treatment with the vaccine was 
comparable to treatment with PPA. 
 
3.2 INTRODUCTION 
 
  The development of urethral sphincter mechanism incompetence (USMI) in 
female dogs is a prevalent sequelae after ovariectomy or ovariohysterectomy (hereafter 
referred to as ovariectomy), with incidences reported between 5.7-20% in ovariectomized 
bitches (Arnold et al., 1992, Thrusfield 1985). In comparison, only 0-1% of intact bitches 
develop USMI (Thrusfield 1985). After ovariectomy, urethral closure pressure decreases, 
even in bitches who remain continent (Arnold et al., 1997). However, urethral closure 
pressure is significantly more reduced in bitches with USMI (Richter and Ling, 1985).  
Urethral closure pressure is normally maintained by sympathetic activation of α1 
adrenoreceptors in the urethral smooth muscle (Hashimoto et al., 1992). Therefore, the 
most common current method of treating USMI is with α-adenergic agonists, specifically 
phenylpropanolamine (PPA).  PPA mimics the effect of catecholamines by activating α1 
adrenoreceptors in the urethral smooth muscle, effectively increasing urethral closure 
pressure and restoring continence. Unfortunately, PPA is not completely effective in the 
treatment of USMI (Arnold et al., 2009, Scott et al., 2002). In addition, PPA is not 55 
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selective for α1 adrenoreceptors within the urinary tract. Undesired vascular smooth 
muscle contraction from PPA administration elsewhere in the body, including blood 
vessels, can result in hypertension (Flavahan, 2005). Other reported side effects of PPA 
in dogs include anorexia, emesis and weight loss, lethargy and behavior changes, and 
proteinuria (Pegasus Laboratories Inc., 2011). Another clinical difficulty with the use of 
PPA is the  four hour half-life (Hussain et al., 1987) that requires dosing every 8-24 hours 
to maintain therapeutically effective urethral closure.  This frequent administration can be 
frustrating for owners because treatment must be continued for the remainder of the dog's 
life. 
  Ovariectomy results in elevated concentrations of pituitary luteinizing hormone 
(LH) because there is no gonadal negative feedback. The canine urinary tract has LH 
receptors (Coit et al., 2009, Ponglowhapan et al., 2007, Reichler et al., 2007), and it has 
been postulated that elevated gonadotropins may contribute to the development of USMI 
(Reichler et al., 2003). Treatment of bitches with GnRH agonists downregulate LH 
secretion for prolonged periods of time (Concannon, 1993) and restores continence to 
incontinent bitches for approximately 250 days (Reichler et al., 2003, Reichler et al., 
2006a). Similarly to PPA, efficacy of GnRH agonists for the treatment of USMI is not 
completely effective. However, unlike PPA, no adverse effects to GnRH agonists have 
been reported. 
There are other methods reported to decrease LH concentrations that may also 
treat USMI, such as immunization against GnRH.  Immunization against GnRH elicits 
the synthesis of GnRH neutralizing antibodies, which prevent GnRH from binding to 56 
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GnRH receptors and consequently prevent the synthesis of LH (Fürst et al., 1994). In 
2004, a commercial GnRH vaccine was launched in the United States (Canine 
Gonadotropin Releasing Factor Immunotherapeutic
®; Pfizer Animal Health USA). This 
vaccine was labeled for the treatment of benign prostatic hyperplasia in intact male dogs, 
but it has also been shown to decrease testosterone concentrations in intact male dogs for 
approximately 20 weeks (Donovan et al., 2012) and to safely terminate pregnancy in 
bitches (Chew and Purswell, 2010).  
  The objectives of this study were to determine (a) whether GnRH immunization 
will maintain continence in incontinent ovariectomized bitches and (b) whether GnRH 
immunization controls USMI as effectively as phenylpropanolamine. It was hypothesized 
that GnRH immunization would effectively maintain continence for a prolonged duration 
and that it would be as effective as phenylpropanolamine for the treatment of USMI. 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Animals and Vaccination 
  Sixteen privately-owned ovariectomized bitches were enrolled at Oregon State 
University's Veterinary Teaching Hospital for this study. A diagnosis of incontinence 
following ovariectomy was confirmed through veterinary medical  records. At the time 
the bitches were recruited for the study, all were being treated with PPA (Proin
®; PRN 
Pharmacal, Pensacola, FL) to maintain continence. Clinical health was confirmed in all 57 
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dogs by a complete blood count, biochemistry panel, urinalysis, and urine culture at the 
beginning and end of the study.  
  Vaccinated dogs (n=11) received 1 mL Canine Gonadotropin Releasing Factor 
Immunotherapeutic
® (Pfizer Animal Health)  subcutaneously over the lateral thorax and  
were re-immunized 4 weeks later. Control dogs (n=5) received 1 mL saline over the 
lateral thorax and were injected again 4 weeks later. Animals were closely monitored by 
their owners for adverse reactions. One treatment dog developed tachypnea for 24 hours 
after initial vaccination and another treatment dog demonstrated impaired movement due 
to soreness for one week after initial vaccination. These two dogs did not receive a 
second vaccination and were excluded from further study. 
3.3.2 Study Design and Sample Collection 
  Venous blood samples were collected from all dogs prior to each injection (0 and 
4 weeks) and again at 6, 8, 10, 12, 16, 20, and 24 weeks after initial vaccination. Blood 
samples were divided into Vacutainer
® clot tubes (02-685-A, Fisher Scientific Co.) to 
obtain serum and Vacutainer
® EDTA tubes (02-683-99A, Fisher Scientific Co.) to obtain 
plasma. After centrifugation, serum and plasma were separated and frozen at -20°C until 
analysis. 
   Vaccinated dogs discontinued PPA use two weeks after the second injection, and 
control dogs remained on PPA for the duration of the study. All vaccinated dogs did not 
take PPA for at least one week after PPA was discontinued; once the dog became 
incontinent again, PPA administration was resumed. 58 
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  Owners reported the frequency of incontinent episodes before any treatment for 
incontinence was initiated, and they also recorded all episodes of incontinence for the 
duration of the study. For vaccinated dogs that maintained continence after PPA 
discontinuation, the frequency of incontinent episodes before any treatment was initiated, 
during treatment with PPA (week 0 through week 6 of the study), and during treatment 
with the GnRH vaccine (week 7 through week 13 of the study) were compared to 
determine the efficacy of each treatment type. 
3.3.3 Sample Assays 
Serum samples were used to measure GnRH antibody titers, determined by 
ELISA using a technique modified from Elhay et al. (2007). Briefly, 96-well microtiter 
plates were coated with 100 µL of 5 µg/mL of LH-RH (71447-49-9, Sigma, St. Louis, 
MO, USA) in sodium bicarbonate buffer (pH 8.0) at 4ºC overnight.  After incubation, 
plates were washed with phosphate-buffered saline containing 0.05% Tween-20 (TPBS) 
(pH 8.0). Plates were then incubated for 1 hour at 20ºC with serum samples in duplicate 
diluted in a buffer containing 0.5% bovine serum albumin (9048-46-8, Sigma, St. Louis, 
MO, USA) to yield final serum dilutions ranging from 1:8 to 1:1024.  After tapping dry, 
antibodies were detected using horseradish peroxidase protein G conjugate (HRP) (10-
1223, Invitrogen, Camarillo) diluted at 1:2000 in serum dilution buffer for 1 hour at 37ºC.  
After a final wash with TPBS, HRP was visualized with 100 µL of ABTS peroxidase 
substrate (50-66-01, KPL, Gaithersburg, MD, USA). Absorbances were read at 405 nm 
using a spectrophotometer (FLUOstar Omega, BMG Labtech Inc., San Francisco, CA, 59 
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USA) and each serum sample was measured in duplicate. The cutoff for seropositivity, 
defined in this study as the upper limit of a 99% confidence interval above the mean 
negative control level, was calculated using the methods of Frey et al. (1998). Serological 
results were expressed as the reciprocal of the highest twofold serial dilution above the 
calculated cutoff and linearized using a base-2 logarithmic scale. 
Plasma samples were analyzed for LH concentrations in duplicate using an 
ELISA kit for canines (LH-Detect
®; Repropharm, Nouzilly, France) and performed 
according to the manufacturer's instructions. The limit of detection was 0.12 ng/mL. 
Optical densities of the scale of standards and the samples were linearized using a base-e 
logarithmic scale and then back-transformed to determine the ng/mL LH concentration of 
each sample using a standard curve. 
3.3.4 Statistical Analysis 
  Serum GnRH antibody titers were compared between the vaccination and control 
group using Fisher's exact test (GraphPad QuickCalcs Software, La Jolla, CA, USA). 
Plasma LH concentrations were compared between the vaccination and control group as a 
repeated measure using PROC MIXED in SAS (Version 9.2, SAS Institute Inc., Cary, 
NC, USA). Fixed effects in the repeated measure model were whether the animal was 
vaccinated, time after first vaccination, and the interactions between vaccination and 
time. A first order heterogeneous autoregressive variance-covariance structure was fitted 
for repeated measurements within animals. The frequency of incontinent episodes before 
initial treatment, treatment with PPA, and treatment with the vaccine were compared as a 60 
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repeated measure using PROC MIXED in SAS. The fixed effect of the repeated measure 
model was the treatment type. Significance was defined as p<0.05. 
 
3.4 RESULTS 
 
  The signalment, treatment, and result of treatment for all bitches is provided in 
Table 3.1. There were no differences between size, age, weight, age at ovariectomy, or 
interval between ovariectomy and incontinence in bitches from the vaccinated and 
control groups. There was no change in clinical health over the duration of the study as 
determined by a complete blood count, biochemistry panel, urinalysis, and urine culture 
(data not shown). 
As mentioned in the methods, two dogs were withdrawn from the study after the 
initial vaccination due to adverse reactions ( tachypnea and prolonged soreness). Eight of 
the nine remaining dogs experienced minor side effects, including lethargy, swelling 
and/or soreness at the injection site, and decreased appetite. Three dogs that experienced 
minor side effects following the initial vaccination were given diphenhydramine at 1 
mg/kg intramuscularly in conjunction with the booster vaccine, and owners reported a 
decrease in adverse reactions following the second vaccination.  
  Four out of nine vaccinated dogs remained continent after discontinuation of PPA. 
One dog became incontinent again 14 weeks after PPA was discontinued and received a 
third GnRH vaccination. Incontinent episodes did not occur after the third vaccination 61 
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and she remained continent through the end of the study. The other three dogs remained 
continent through the end of the study (24 weeks). All five control dogs on PPA remained 
continent for the duration of the study. Of the four dogs where the vaccine had an effect, 
episodes of incontinence before treatment was initiated, during PPA treatment, and 
during vaccine treatment were compared. There were significantly less accidents when 
the dog was treated with PPA (p=0.02) or the vaccine (p=0.01) compared to before 
treatment initiation. There was no significant difference in treatment between PPA and 
the vaccine (Figure 3.1). 
  All dogs were seronegative for antibodies against GnRH prior to the first 
vaccination and all control dogs remained seronegative for the duration of the study. All 
nine vaccinated dogs developed a GnRH antibody titer after initial vaccination that 
peaked  at week 6, and all but one dog still had an antibody titer at the end of the study 
(Figure 3.2). At week 0, plasma LH concentration was 5.06 ng/mL ± 1.99 ng/mL. 
Following GnRH immunization, plasma LH concentration declined to basal levels 
(Figure 3.3). Control dogs maintained significantly higher LH concentrations (Figure 3.3)  
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Table 3.1. Signalment of 16 ovariectomized dogs diagnosed with USMI 
Dog  Breed  Weight 
(kg) 
Current 
Age 
(Years) 
Age at 
Ovariectomy 
(Years) 
Interval from 
Ovariectomy to 
Incontinence (Years) 
Study 
Treatment  Treatment Effect 
1  Greyhound  26  9  1  5  Vaccine  Continent 
2  Golden Retriever  28  5  0.5  2.5  Vaccine  Continent 
3  Border Collie  18  11  1  0  Vaccine  Incontinent 
4  Pitbull  24  9  0.75  3.25  Vaccine  Incontinent 
5  Pitbull Mix  20  1  0.25  0.25  Vaccine  Incontinent 
6  Doberman Mix  35  8  0.5  3.5  Vaccine  Incontinent 
7  Australian Cattle Dog  25  7  0.5  0  Vaccine  Continent 
8  Springer Spaniel  19  9  4.5  0.5  Vaccine  Continent 
9  Viszla  19  6  0.58  3.92  Vaccine  Incontinent 
10  Siberian Husky Mix  24  12  0.5  6.5  PPA  Continent 
11  Rottweiler Mix  34  8  0.5  3.5  PPA  Continent 
12  Labrador  27  6  0.5  2.5  PPA  Continent 
13  Weimaraner  27  9  4  3  PPA  Continent 
14  Weimaraner  29  6  2  3  PPA  Continent 
15  Australian Shepherd  25  6  0.5  3.5  Vaccine  Rxn; Withdrawn 
16  Australian Shepherd  20  9  0.5  2.5  Vaccine  Rxn; Withdrawn 
               
  Mean  25  7.56  1.13  2.71     
  Standard Deviation  5.09  2.61  1.29  1.81     
  Range  18-35  1-12  0.25-4.5  0-6.5     63 
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Figure 3.1. Comparison of the number of incontinence episodes (± SD) that occurred in 
four out of nine vaccinated dogs before any treatment was previously initiated, during 
treatment with phenylpropanolamine (PPA) from week 0-6 of the study, and during 
treatment with the vaccine from week 7-13 of the study. There were significantly fewer 
accidents when treated with PPA (p=0.02) and the vaccine (p=0.01) compared to before 
treatment initiation. There was no difference between treatment with PPA and treatment 
with the GnRH vaccine (p=0.88) 
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Figure 3.2. Serum GnRH antibody titer (Mean ± SEM) in control (□) and vaccinated (●) dogs prior to each injection (0 and 4 
weeks) and at weeks 6, 8, 10, 12, 16, 20, and 24 following initial treatment. *p<0.05 compared to controls  
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Figure 3.3. Plasma LH concentrations (Mean ± SEM) in control (□) and vaccinated (●) dogs prior to each injection (0 and 4 
weeks) and at weeks 6, 8, 10, 12, 16, 20, and 24 following initial treatment. There was a significant effect of the vaccine on LH 
concentrations (p=0.0004). *p<0.05 compared to controls66 
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3.5 DISCUSSION 
 
  The development of USMI after ovariectomy in female dogs is a significant 
problem. Treatment with PPA is not completely effective, must be administered 
frequently to have a therapeutic effect, and may cause adverse side effects. Therefore, 
there is a need to find a safe therapy with a longer duration of effect for the treatment of 
USMI. In this study, we demonstrated that GnRH immunization was able to maintain 
continence in 44% of incontinent ovariectomized dogs for 14 weeks or longer with an 
efficacy comparable to PPA in those dogs. 
  Immunization against GnRH did not maintain continence in all vaccinated dogs, 
which is similar to the effects of GnRH agonists on USMI. Reichler et al. (2003, 2006a) 
demonstrated 41-54% efficacy for the treatment of USMI by reducing LH concentrations 
through the use of GnRH agonists. Reducing LH concentrations does not directly 
improve urethral pressure, but rather increases bladder threshold volume (Reichler et al., 
2006b). While it is understood that the decrease in urethral pressure as a result of 
ovariectomy plays a role in the development of USMI (Arnold et al., 1997), it has also 
been determined that ovariectomy results in changes to the bladder, specifically an 
increased collagen content and a reduced response of the detrusor muscle to muscaniaric 
stimulation in vitro (Coit et al., 2008). Therefore, it is possible that the changes in the 
bladder as well as the urethra may both contribute to the development of USMI. It is not 
known why increasing bladder threshold volume through reducing LH concentrations is 
enough to restore continence in some but not all ovariectomized bitches, but in these 67 
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dogs, an increase in bladder threshold volume may not be enough to compensate for 
decreased urethral pressure.  
  This study did not determine how long the GnRH vaccine had an effect on urinary 
incontinence because three of the four continent dogs were still continent at the end of the 
study. A previous study looking at the effect of the GnRH vaccine in intact male dogs 
found that 20 weeks after initial vaccination, antibody titers were insignificant compared 
to pre-vaccination and testicular volume was back to pre-vaccination measurements, 
indicating the vaccine had lost its effect by that point (Donovan et al., 2012). Therefore, it 
was expected that the GnRH vaccine would also lose its effect around week 20 in the 
female dogs in this study. On the contrary, all vaccinated dogs except one still had a 
GnRH antibody titer and all dogs still had basal LH concentrations by week 24, 
indicating that the effect of the GnRH vaccine may be further prolonged in females 
compared to males.   
  Side effects were experienced by nearly all vaccinated dogs in this study. While 
most side effects were minor and resolved without treatment after 24 hours, two dogs 
experienced adverse reactions that resulted in withdrawal from the study. Safety of the 
GnRH vaccine at 1 mL (n=237) and 2 mL (n=24) doses was demonstrated in intact male 
dogs with no significant reactions or adverse events observed (Pfizer Animal Health, 
2004). However, mild injection site swelling occurred in 10% of the intact male dogs at 
the 1 mL dose and in 8.3% of the intact male dogs at the 2 mL dose. Minor side effects 
were also reported when the vaccine was used for pregnancy termination in bitches 
(Chew and Purswell, 2010). 68 
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  In conclusion, GnRH immunization was effective in maintaining continence in 
44% of incontinent ovariectomized dogs, and in these dogs, treatment with the vaccine 
was comparable to treatment with PPA. Because of low product sales, the GnRH vaccine 
investigated in this study is no longer commercially available. Efforts should be made to 
bring an available GnRH vaccine to market for the treatment of urethral sphincter 
mechanism incompetence.  
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CHAPTER IV 
 
CONCLUSION AND FUTURE STUDIES 
 
  We investigated two clinical applications of GnRH immunization in dogs.    In 
intact males, GnRH immunization decreased testosterone concentrations and testicular 
volume for approximately 20 weeks. In ovariectomized incontinent females, GnRH 
immunization was sufficient to maintain continence in 44% of the bitches studied. Some 
minor and two major reactions occurred after immunization, which were reported to the 
vaccine manufacturer.  Despite these side effects, owners were generally satisfied with 
this treatment option.  It is important to mention that since ending the clinical 
investigation, there have been several requests from owners participating in the study as 
well as new owners and veterinarians interested in purchasing the vaccine to treat their 
incontinent spayed dogs.  Unfortunately, this is not possible as the manufacturer has 
chosen not to continue GnRH vaccine production. With regards to urinary incontinence, 
future studies should investigate methods to prevent this sequelae of ovariectomy from 
developing.  Specifically, it would be interesting to ovariectomize bitches following 
GnRH immunization to observe changes in gonadotropin concentration as well as 
changes in the urethral sphincter mechanism.   
  A problem of all GnRH vaccines investigated to date is that the effects of 
vaccination last for a short duration (weeks to months), which vary considerably based 
upon individual variations in the humoral response to immunization. Developing a GnRH 72 
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vaccine that would last for a long duration (months to years) or be permanent 
(irreversible) would be especially useful not only for treating urinary incontinence and 
other conditions resulting from ovariectomy (such as puppy coat syndrome), but also for 
non-surgically sterilizing dogs (which would completely prevent these post-ovariectomy 
complications). We have demonstrated the efficacy of such a vaccine in male dogs, albeit 
for short term immunosterilization. 
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APPENDIX A: ANIMAL CARE AND USE PROPOSAL 
ACUP ID 4001 
PARTICIPANTS 
 
1. Principal Investigator (PI): Michelle Kutzler, DVM 
2. Department: Clinical Sciences 
3. Principal Investigator’s signature and date: 
4. Project title or course name and number: GnRH immunization for treatment of 
hormone-responsive urinary incontinence in spayed bitches 
5. Start date: February 1, 2010 Completion date: January 31, 2012 
6. Funding agency if applicable: Morris Animal Foundation 
7. Check all items that apply: 
Death as an end point 
Procedures without the use of appropriate anesthetic, analgesic, or tranquilizing 
drugs. 
Multiple survival surgery 
Prolonged or unusual restraint or deprivation 
Endangered species 
8. Provide the following for the PI and all participants who will be working with the 
animals. Proposal will not be approved if the information is incomplete. For class 
activities list only the instructional staff. 
Participant Name: Jana Gordon Date:12/8/09 
Department: Clinical Sciences 
Job Title: Assistant Professor  
E-mail Address: jana.gordon@oregonstate.edu 
Work Telephone: 7-4812  
Education : Yes Occupational Health : Yes 
 
Participant Name: Michelle Kutzler Date: 12/8/09 
Department: Clinical Sciences 75 
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Job Title: Associate Professor  
E-mail Address: michelle.kutzler@oregonstate.edu 
Work Telephone: 7-6952  
Education : Yes  Occupational Health : Yes  
 
JUSTIFICATION FOR USE OF LIVE VERTEBRATES 
1. Common name of animal(s) used: Dog 
 
2. Number of animals needed: First year:40 Second year:40 (same animals) Third year: 
40 (same animals) 
 
3. What is the scientific justification for the number of animals proposed for this ACUP 
(e.g. number of students in the class, data sources, experimental design, etc.)? 
The numbers requested are based on the minimum numbers needed for statistical 
analysis purposes. There will be two groups consisting of 20 vaccinated dogs and 
20 control-treated dogs receiving traditional treatment of daily 
Phenylpropanolamine (PPA) medication. Prior to treatment, we anticipate that LH 
concentrations will range between 0.5 and 31.2 ng/mL (median7.3 ng/mL) based 
upon the data reported by Reichler et al (2006). In the 2006 Reichler study, 
following treatment with a GnRH analogue (leuprolide acetate), median LH 
concentrations were 0.72 ng/mL. Assuming similar values with equal variances 
and a standard deviation of 1.0 ng/mL in the proposed research, twenty dogs per 
group are needed for the study to have a power of 5% (alpha (1-tailed) set at 
0.05). 
 
 I expect the vaccine to have similar results to leuprolide because the effect of 
treatment is the same (decreased LH concentrations), however the mechanism of 
action by which the LH concentrations are decreased is different. With leuprolide, 
the GnRH receptors are overstimulated and then down-regulated, resulting in an 76 
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eventual decrease in LH concentrations. With the GnRH vaccine, antibodies 
against GnRH are formed which block the ability for GnRH to bind to its receptor 
and thereby prevent LH secretion. Leuprolide is a human drug that is used in an 
extra-label manner in veterinary medicine. It is effective at treating LH-
responsive incontinence but it is also very expensive (because it is a human drug), 
the efficacy is short-lived (must be repeated several times a year) and has some 
side effects associated with the initial stimulation of GnRH receptors 
(predominately within the cardiovascular system as described with humans 
(http://www.drugs.com/pro/leuprolide.html). None of these would be the expected 
with the GnRH vaccine being tested as it is labeled for use in dogs, is expected to 
last at least 6 months and probably for much longer than that (similar to other 
vaccines we use in dogs) and does not have any side effects. 
 
4. Why are live vertebrates used and what non-animal alternatives were considered for 
this research or course? 
There are no non-animal alternatives. Live animals are needed to determine if the 
response to vaccination alleviates the symptoms of their disease (specifically 
urinary incontinence). 
 
What is the justification for use of this species? 
The study must be perfomed in the target species (dogs) because this disorder 
(postovariohysterectomy hormone-responsive urinary incontinence) occurs 
spontaneously in this species following spaying. 
 
6. Does this proposal duplicate a previous use of animals in teaching or research? No 
If yes, why is duplication necessary (e.g. new group of students)? 
 
7. Will animals experience discomfort, distress or pain during the proposed use, 
according to the following categories as defined by the Animal Welfare Act?  77 
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No discomfort, distress or pain involved (e.g. routine short term procedures 
involving manual or mechanical restraint; injections to administer substances, 
implant ID tags or collection of biological samples, such as blood, urine, stomach 
contents, etc.) 
 
ANIMAL CARE 
1. Where will the animals be housed? List building, floor, room, barn, corral, paddock, or 
pasture as applicable. 
Dogs will be housed with their owners. 
 
2. Who will care for the animals? List person’s name and contact information e.g. work 
phone, pager or e-mail. 
Dogs will cared for by their owners. 
 
3. If other than LARC, who will provide veterinary care of sick, or injured animals? 
Provide name of individual(s) and their contact information. 
Dogs will receive regular veterinary care from their regular veterinarian and will 
receive additional care specific to their hormone-responsive urinary incontinence 
as it pertains to this research by Dr. Jana Gordon, small animal internal medicine 
specialist. 
 
ANIMAL USE 
1. What are the objectives and significance of the proposed research or instruction using 
animals? Avoid the use of acronyms and undefined abbreviations. Summarize in terms 
that a non-scientist would understand. 
 
Objective 1: To measure serum GnRH antibody titers and luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH) concentrations in spayed bitches 
following treatment with Canine Gonadotropin Releasing Factor 78 
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Immunotherapeutic® (Pfizer Animal Health) vaccine or control 
(phenylpropanolamine (PPA))-treated. PPA is the current recommended treatment 
for hormone-responsive urinary incontinence in dogs. 
 
Objective 2: To measure the efficacy of each treatment (vaccine versus control 
(PPA)) in restoring continence to incontinent, spayed bitches. 
Phenylpropanolamine (PPA) is a non-hormonal medication commonly used in 
male and female dogs to treat hormone-responsive urinary incontinence. In 1999, 
the federal Food and Drug Administration banned PPA for human use, which 
significantly limited the veterinary sources for this drug. Currently, PPA is only 
available through veterinary compounding pharmacies. Dogs with hormone-
responsive incontinence need to remain on either PPA for the rest of their lives. 
The significance of the proposed study is to prove the effectiveness of a 
commercially available vaccine labeled for use in intact male dogs with benign 
prostatic hyperplasia in the treatment of the previously mentioned conditions in 
neutered dogs. These conditions impact the overall health and well being of 
companion animals, and also the owners of such pets. In addition to the 
aforementioned benefits on animal health and longevity, an additional future 
application of this vaccine in canine population control. 
 
The Canine Gonadotropin Releasing Factor Immunotherapeutic vaccine is 
developed for use and has been in male client dogs. There is no risk to using this 
vaccine in client-owned female spayed dogs that would not be observed in the 
male dogs it has already been used in. The justification for using it in client-
owned dogs is that this disease (urinary incontinence) is spontaneously occurring 
in the client-owned dog population. Research dogs are not available that have this 
problem. This disease is naturally-occurring and warrants treatment with a 
product that is already being used in client-owned male dogs. Although there has 
not been any published research using this vaccine in female dogs yet, a scientific 79 
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abstract by Chew & Purswell reporting the safety and efficacy of this vaccine in 
reducing serum progesterone concentrations in intact female dogs will be 
presented at the 2010 Society for Theriogenology meeting. 
 
2. Where will the animal procedures be conducted? List all sites including building, room 
or any other location. 
Animal procedures will be conducted at the Small Animal Veterinary Teaching 
Hospital at Oregon State University under the supervision of Dr. Jana Gordon. 
 
3. Describe in detail all routine procedures involving the animal(s). Routine procedures 
are those that cause minimal discomfort or pain to the animal. Examples include: restraint 
techniques, tagging, dosing (list agents, dosages and routes of administration). 
Venous blood (3-5 mL) will be drawn from all participant animals to determined 
baseline serum GnRH antibody titers along with LH and FSH concentrations. 
Blood samples will be collected prior to subcutaneous administration of Canine 
Gonadotropin Releasing Factor® vaccine (1 mL). Dogs in the control treated 
group will receive phenylpropanolamine (PPA) at a dose of 1 mg/kg of body 
weight orally twice daily. Only dogs in the vaccine group will receive a vaccine 
treatment. Four weeks post initial administration of the Canine Gonadotropin 
Releasing Factor vaccine, a second dose will be administered to the dogs in the 
vaccine group. Both doses will be administered aseptically subcutaneously, as per 
the manufacturer’s directions. Venous blood (3-5 mL) will be drawn from all 
participant animals for the determination of serum GnRH antibodies along with 
LH and FSH concentrations every 8 weeks for the duration of the study (two 
years). 
 
Twenty privately-owned, spayed bitches exhibiting symptoms of hormone-
responsive urinary incontinence will be vaccinated as described above. Twenty 
privately-owned, spayed bitches with the same diagnosed condition will serve as 80 
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controls as described above. In addition to the measurement and comparison of 
GnRH antibody titers and gonadotropin concentrations (as described in the 
previous paragraph), the owners of participating animals will be heavily relied 
upon to determine the frequency of incontinent episodes. In order to reduce 
contributing factors in the occurrence of incidences of incontinence, a survey will 
be completed by bitch owners prior to the start of the study and on all follow-up 
visits. The survey will include such information as the animal’s feed and water 
intake, daily activities, changes in environment, and average number of 
incontinent episodes along with situations surrounding such episodes. 
 
The risks and the potential consequences for the dogs participating in this study 
will be explained to the owners through the owner consent form. Understanding 
these risks and the potential consequences will be implied with the owner’s 
signature on the owner consent form. Owners are encouraged to contact Dr. 
Gordon or Dr. Kutzler if they have any questions or concerns regarding 
participation in this research. Dr. Kutzler will confirm that all dogs enrolled in the 
study have a signed owner consent form. Dr. Gordon will also confirm that 
owners complete the owner survey forms at each monthly office visit with their 
regular veterinarian during their participation in this study. 
 
4. Describe method of euthanasia and carcass disposal. 
Not applicable 
 
5. Check any of the following that will involve the animal. Complete and submit all 
applicable supplements. 
Discomfort, Distress, or Pain (non-surgical). (Complete Discomfort, Distress, 
Pain Supplement) 
Antibody production (Complete Antibody Production Supplement) 81 
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Breeding colony or sentinel animals (Complete Breeding Colony & Sentinel 
Animal supplement) 
Death of the animals as an indicator or data point in the research or instruction 
(Complete the Death as an End Point Supplement) 
Field studies (Complete the Field Studies Supplement) 
Surgery (Complete the Surgery Supplement) 
 
6. The appropriate compliance committee will be notified if any of the following agents 
are used: 
Biohazards administered to the animal 
Radioactive isotopes administered to the animal 
Infectious agents administered to the animal 
Carcinogens administered to the animal 
Recombinant DNA products administered to the animal 
 
DISCOMFORT, DISTRESS, AND PAIN SUPPLEMENT (DDP) 
(FILL OUT ONLY IF APPLICABLE) 
1. Describe in detail all procedures that may cause discomfort, distress or pain. 
We do not anticipate that any of the procedures described will cause discomfort, 
distress or pain. This vaccine is licensed for use in dogs but not labeled for 
treatment of these conditions. Safety of this product has been demonstrated when 
administered according to the label directions. According to the vaccine package 
insert, when administered as a 2X overdose (2 mL), no significant systemic 
reactions or adverse events were observed over a 14-day post-treatment 
observations period. Preliminary safety trials conducted by the vaccine 
manufacturer involving 237 treatments resulted in approximately 10% mild 
injection site swellings that were only apparent by palpation, and resolved without 
treatment. No pain was reported upon injection in a controlled repeated overdose 
study, in which 24 adult dogs received a 2X (2 mL) followed by a second 2X 82 
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overdose 4 weeks later. A total of 4 injection site reactions out of 48 
administrations were observed during the 21-day observation period, and resolved 
without treatment. These mild injection site swellings were only apparent by 
palpation. As with any vaccine, owners should be aware that more serious, 
anaphylactic reactions could occur. 
 
2. Describe all signs of discomfort, distress or pain that will be monitored, and frequency 
of monitoring. 
Owners will be instructed to monitor the dogs for changes following vaccination. 
We anticipate that the changes noticed by the owners will be associated with the 
beneficial effects of vaccination; namely reduced urinary incontinence. Owners 
will complete a survey at the time of each veterinary visit regarding any 
symptoms noticed following vaccination (injection site reactions). If signs of 
discomfort occur, owners are asked to contact their regular veterinarian and to 
notify Dr. Gordon. 
 
3. List all medications (anesthetics, analgesics or tranquilizers) including, dosages, route 
and frequency of administration. 
No medications will be given other than the vaccine in the vaccine-treated group 
unless there is a vaccine reaction. If anaphylaxis develops, epinephrine at a dose 
of 0.1 mL/10 pounds of body weight will be administered once intramuscularly or 
intravenously. Additional veterinary care for the treatment of a vaccine reaction 
will be determined by Dr. Gordon. For the control group, PPA (1 mg/kg) will be 
orally administered by the owners twice daily for the customary treatment of 
hormone-responsive urinary incontinence. 
 
4. What refinement(s) to procedures were considered to minimize discomfort, distress or 
pain to the animals? 83 
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Patients will be followed on a every other month basis to minimize discomfort or 
distress involved with more frequent veterinary office visits. Every other month 
visits is the minimum number of observations (blood sample collections and 
owner survey results) necessary to demonstrate efficacy of this immunologic 
treatment for post-ovariohysterectomy hormone-responsive urinary incontinence. 
 
5. What information source(s) or literature searches were used to locate alternatives to 
procedures involving pain or distress to the animal? The OSU-IACUC requires 
documentation of methods and sources to find acceptable alternatives including: a list of 
data bases searched, dates of search and key words used. 
On December 7, 2009, a literature search of PUBMED was conducted. Using the 
keywords "dog, GnRH, vaccine or vaccination", there were a total of 12 hits and 
of these only 9 actually pertained to dogs. The most recent article describes the 
widespread application of a combined GnRH and rabies vaccine for both 
population control and rabies prevention in dogs (Wu X et al 2009). Two of the 
nine are review articles (Kutzler MA et al 2006 and Naz RK et al 2005). The 
remaining six articles all refer to original research in male dogs (not female dogs) 
and half of these (3 of 6 articles) were written by the research and development 
team that created the GnRH vaccine to be tested (Walker J et al 2007; Zeng W et 
al 2007 and Yu M et al 2005). 
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APPENDIX B: ANIMAL CARE AND USE PROPOSAL AMENDMENTS 
 
Animal Care and Use Amendment Form 
Oregon State University Institutional Animal Care and Use Committee 
 
Use this form to make a change to an Animal Care and Use Proposal. Return completed 
form to IACUC@oregonstate.edu or send to IACUC, Office of Research Integrity, 308 
Kerr Administration, Corvallis, OR 97331  
 
Principal Investigator: Michelle Kutzler Telephone: 7-1401  
 
E-mail: michelle.kutzler@oregonstate.edu  
 
Department/College: Animal Sciences Granting Agency: Collie Health Foundation  
 
ACUP Number: 4001  
 
Project Title: GnRH immunization for treatment of hormone responsive urinary 
incontinence in spayed bitches  
 
Which type(s) of changes in protocol are being proposed? Check all that apply.  
Addition/deletion of procedure  
 
 (Describe)  
 
We would like to change the frequency of blood samples collection from weeks 0, 4, 8, 
16, 24, 32, 40, 48, 56 to the weeks 0, 4, 6, 8, 10, 12, 16, 20, 24. The rationale for this 
change is based upon our preliminary results that show the highest titer at week 8 and no 
titer at week 24. The change in frequency will allow us to more accurately determine 
when the peak titer occurs. There is no increase in the number of blood samples 
collection as this remains a total of 9 blood samples. In addition, the change in protocol 
proposed reduces the study duration for each participant.  
Describe all proposed change(s) in detail. If change in personnel, identify personnel no 
longer involved and new personnel. New personnel must satisfy educational and 
occupational health requirements before approval will be granted. If change(s) proposed 
add any procedures that have the potential to cause animal pain or distress, then you must 
describe the methods and sources by which alternatives to these procedures have been 
sought. Please review the original protocol and confirm that all principal investigator 
assurances apply to proposed change(s). (Attach additional sheets if necessary.)  
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Justify the need for these proposed changes.  
 
We would like to change the frequency of blood samples collection from weeks 0, 4, 8, 
16, 24, 32, 40, 48, 56 to the weeks 0, 4, 6, 8, 10, 12, 16, 20, 24. The rationale for this 
change is based upon our preliminary results that show the highest titer at week 8 and no 
titer at week 24. The change in frequency will allow us to more accurately determine 
when the peak titer occurs. There is no increase in the number of blood samples 
collection as this remains a total of 9 blood samples. In addition, the change in protocol 
proposed reduces the study duration for each participant. IACUC Amendment Form July 
21, 2003  
 
IACUC Action: VR Approved OSU Attending Veterinarian 6/11/12 
 
Animal Care and Use Amendment Form  
Oregon State University Institutional Animal Care and Use Committee 
 
Change in Personnel 
 
Use this form to make a change to an Animal Care and Use Proposal. Return completed 
form to IACUC@oregonstate.edu  or send to IACUC, Office of Sponsored Programs and 
Research Compliance, 312 Kerr Administration, Corvallis, OR 97331  
 
Principal Investigator:  Michelle Kutzler             Telephone: 7-1401   
  E-mail michelle.kutzler@oregonstate.edu 
 
Department/College: Animal Sciences                      Granting Agency: Collie Health Fdtn 
 
ACUP Number(s): 4001 
Project Title:   GnRH  immunization  for  the  treatment  of  hormone-responsive  urinary 
incontinence in spayed bitches 
 
Copy and paste the box for all new staff that will be added. Complete as noted in the 
instructions: 
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Name   Caitlin Donovan  Department   Animal Sciences 
Work Address   315 Withycombe Hall 
Work email  donovaca@onid.orst.edu 
Work phone 
number 
978-994-2754 (cell) 
Role (PI, 
laboratory staff, 
post-doc, student, 
etc.) 
Master's student 
Animal Welfare 
Education 
Completed (Y/N) 
Y  OHS Enrollment  
Completed                         
(Y/N)  
Y 
Experience and 
Qualifications 
For this project, she will be assisting Dr. Gordon by restraining dogs for 
sample collection. She has completed her training in the human use of 
animals in research and the animal contact and occupational health 
questionnaire. She received a BS in Animal Science from the University 
of Massachusetts (Amherst). For her undergraduate Honor's thesis, she 
was involved with research on alpacas which she performed 
reproductive ultrasound exams, collected blood samples, and general 
herd health maintenance. She was also involved with FAMACHA 
research with sheep and goats. She is a multi-decade dog, cat, and horse 
owner, with experience in pet husbandry and basic veterinary care. She 
has worked as a Teaching Assistant both at UMass and at Oregon State 
University in Camelid Studies and Introduction to Animal Science, 
respectively. 
 
IACUC Approval 6/11/12 
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APPENDIX C: OWNER CONSENT FORM 
INFORMED CONSENT FORM FOR ANIMAL OWNERS 
 
PROJECT TITLE:  
Efficacy of GnRH vaccination for the treatment of urinary incontinence in spayed female 
dogs 
INVESTIGATORS:   
Dr. Jana Gordon, DVM, DACVIM; Dr. Michelle Anne Kutzler, DVM, PhD, DACT 
 
PURPOSE OF STUDY:  
The purpose of this study is to investigate the effectiveness of a commercially available 
canine GnRH vaccine in suppressing the production of LH in spayed female dogs.  We 
hypothesize that this vaccine will induce serum neutralizing antibody titers against GnRH 
and that a decrease in LH concentrations will correlate with a decrease in symptoms 
associated with urinary incontinence.  To test these hypotheses, spayed female dogs will 
be vaccinated twice or treated with phenylpropanolamine (PPA; traditional treatment as 
prescribed by the animal’s veterinarian) and serum GnRH antibody titers as well as LH 
concentrations will be measured nine times over 6 months.  
 
PURPOSE OF FORM:  
You are being asked to give your consent to have your dog participate in a research 
study. This consent form gives you the information you will need to help you decide 
whether to allow your animal to participate. Please read the form carefully. You may ask 
any questions about the research, the possible risks and benefits, rights as a volunteer 
participant, and anything else that is not clear. When all of your questions have been 
answered, you can decide if you will allow your animal to be in this study or not. 
 
WHAT WILL HAPPEN IN THE STUDY:   
The GnRH vaccine used for this research is the Canine Gonadotropin Releasing Factor 
Immunotherapeutic (Pfizer Animal Health). Ten spayed female dogs will receive two 
subcutaneous injections of this GnRH vaccine.  Another ten spayed female dogs will be 
treated with PPA (as prescribed by the animal’s veterinarian).  Venous blood samples (6-
12 mL) will be collected at the Oregon State University Small Animal Hospital prior to 
each vaccination and then at 6, 8, 10, 12, 16, 20, and 24 weeks from the initial visit. 
 
RISKS OF THE STUDY:  
This vaccine is licensed for use in dogs but not labeled for treatment of these conditions.  
Safety of this product has been demonstrated when administered according to the label 
directions.  According to the vaccine package insert, when administered as a 2X overdose 
(2 mL), no significant systemic reactions or adverse events were observed over a 14-day 
post-treatment observations period.  Preliminary safety trials conducted by the vaccine 89 
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manufacturer involving 237 treatments resulted in approximately 10% mild injection site 
swellings that were only apparent by palpation, and resolved without treatment.  No pain 
was reported upon injection in a controlled repeated overdose study, in which 24 adult 
dogs received a 2X (2 mL) followed by a second 2X overdose 4 weeks later.  A total of 4 
injection  site  reactions  out  of  48  administrations  were  observed  during  the  21-day 
observation period, and resolved without treatment.  These mild injection site swellings 
were only apparent by palpation.  Although there has not been any published research 
using this vaccine in female dogs yet, a scientific abstract by Chew & Purswell reporting 
the safety and efficacy of this vaccine in reducing serum progesterone concentrations in 
intact female dogs was presented at the 2010 Society for Theriogenology meeting. 
As with any vaccine, owners should be aware that more serious, anaphylactic reactions 
could occur.  You should contact your regular veterinarian and the Oregon State Small 
Animal Hospital if any discomfort is observed following vaccination. 
BENEFITS OF THE STUDY:  
The significance of the proposed  research will be to  determine if this treatment  will 
provide  a  long-term,  inexpensive,  simple  and  effective  method  for  the  treatment  of 
hormone-responsive  urinary  incontinence  that  results  from  spaying  female  dogs.  
However,  GnRH  vaccination  may  not  be  effective  for  the  treatment  of  urinary 
incontinence. 
 
IS THERE COMPENSATION FOR PARTICIPATING:   
No. There is no compensation or therapy for injuries included in participation of this study. 
 
ARE THERE ANY COSTS FOR PARTICIPATING:  
There will be no direct financial costs to the owner for participating.  However, 
owners are required to bring their dog to 9 veterinary visits over 6 months, which 
will be paid for by the investigators. 
ALTERNATIVE TREATMENT:  
You should discuss alternative treatment options for your pet’s optimum health and well 
being with your regular veterinarian as this will differ on a case-by-case basis.  
 
EXTENT OF CONFIDENTIALITY OF RECORDS: 
Veterinary-Client records will remain confidential. However, results from this study 
will be reported in a qualitative and quantitative manner with the animal’s and 
owner’s names withheld. 90 
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WITHDRAWING MY ANIMAL FROM THE STUDY:  
Your participation in this study is entirely voluntary and you may withdraw your animal at 
any time. You also understand that your animal may be withdrawn from the study if the 
investigators find it necessary. If your animal is withdrawn from the study for any reason, 
data already collected may continue to be used for research purposes.  You will not be 
treated differently if you decide to not participate in this study. Your decision to participate, 
not participate, or withdraw from the study will not affect your relationship with OSU. 
 
WHAT IF I HAVE QUESTIONS?   
If you have any questions regarding this study, you may contact Dr. Jana Gordon (541-
737-4812) or Dr. Michelle Kutzler (541-737-1401) or your regular veterinarian. I have 
read and understand the foregoing statements and agree to allow my animal to participate 
in this study. My questions about the experiments have been answered to my satisfaction. 
Your signature indicates that this research study has been explained to you, that your 
questions have been answered, that you understand the risks, potential consequences and 
outcomes, and that you agree to allow your animal to be in the study.  You will receive a 
copy of this form.  
 
Animal's Name:__________________________________ 
 
 
Owner’s Printed Name:____________________Signature:_____________________   
 
Date:______ 
Investigator’s Printed Name:  _______________Signature:_____________________   
 
Date:______ 
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APPENDIX D: Presented at the Willamette Valley Veterinary Medical Association 
Meeting, December 2011 (Corvallis, OR) 
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Appendix E: Presented at the Chintimini Kennel Club Meeting, November 2012 
(Corvallis, OR) 
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APPENDIX F: URINARY INCONTINENCE STUDY ADVERTISEMENTS 
Does your dog suffer from urinary incontinence? 
If so, we need you! 
 
 
The Oregon State University Animal and Rangeland Sciences department is currently 
recruiting SPAYED, FEMALE dogs of any age or breed to participate in a study looking at 
an alternative treatment for urinary incontinence. All dogs MUST be: 
  Currently CONTROLLED using Proin (phenylpropanolamine hydrochloride) oral 
tablets for at least 6 months 
  Be free of any health problems that may affect continence 
  Be diagnosed incontinent AFTER spaying by a licensed veterinarian 
All dogs enrolled in the study will need to come to the Oregon State Small Animal Teaching 
Hospital for a total of 9 visits over a period of 6 months. On visits 1 and 9, dogs will receive 
a physical exam and have blood and urine collected for urinalysis, urine culture, complete 
blood count, biochemistry profile, and hormone analysus. On visits 1 and 2, the dog will 
receive a vaccine or placebo and vaccinated dogs will discontinue Proin use on the third 
visit. On visits 3-8, only a blood sample will be taken. Throughout the study period of 6 
months, owners will be given a simple log to fill out daily regarding episodes of 
incontinence. 
 
All veterinary work performed is free to the owner and 6 months of Proin will be given to all 
participants upon study completion. 
For more information or to enroll your dog, take a tab and contact us! Email is the best form 
of communication. 
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APPENDIX G: OWNER SURVEY 
 
PET ID: ________________________________________________________________ 
Owner Information 
Name:__________________________________________________________________ 
Email:__________________________________________________________________ 
Address:________________________________________________________________ 
Phone #: ________________________________________________________________ 
Regular Veterinarian: ____________________________________________________ 
Q1. Pet Name ____________________________________________________________ 
Q2. Breed:_________________________________________ 
Q3. Age: _____________________   
 
Q4. At what age was your pet spayed: (Circle one number) 
0  Less than 3 months  2  6 months to 1 year  4  2 to 4 years  6  Over 6 years 
1  3 to 6 months  3  1 year to 2 years  5  4 to 6 years  7  Don’t know 
 
Q5. Is your pet an indoor or outdoor animal? (Circle one number) 
1  Indoor  2  Outdoor    3    Both     
                
 103 
 
 
101  
Q6. How many other pets are present in your household: (circle one number)   
0  NONE  2  TWO  4  FOUR  6  SIX 
1  ONE  3  THREE  5  FIVE  7  SEVEN OR MORE 
 
Q7. Are there health issues with the other pets present in your household? (Circle a 
number) 
1  Yes  2  No 
 
Q8. If yes to Q7, please specify:  
________________________________________________________________________ 
 
Q9. Please describe the overall health of your pet:_______________________________ 
________________________________________________________________________ 
 
Q10. At what age did symptoms of urinary incontinence develop?  
___________________________ 
 
Q11. If symptoms of urinary incontinence were present at time of pet acquisition, at what 
age did you acquire your pet?  
____________________________ 
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Q11.Before you began treatment, how often did your pet experience episodes of 
incontinence or inappropriate urination? (Circle one number) 
1  Several times per day  3  At least once every other day 
2  At least once a day  4  At least once a week 
 
Q12. Do your pet’s episodes of incontinence generally occur while your pet is awake or 
while sleeping? (Circle one number) 
1  While 
awake 
2  While 
sleeping 
3  While 
awake and 
while asleep 
4  Does not have a general            
time of occurrence  
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APPENDIX H: OWNER DAILY LOG 
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APPENDIX I: PARTICIPATING DOG VACCINE REACTIONS 
 
  Thirteen total dogs were vaccinated and twelve experienced side effects as a result 
of vaccination. Most side effects were minor and included lethargy, tenderness at the 
injection site, and decreased appetite that lasted approximately 24 hours. Other more 
adverse reactions included edema at the injection site, tachypnea, and difficulty moving. 
Vaccine reactions experienced by each dog are summarized in Table I.1. Towards the end 
of the study, diphenhydramine was intramuscularly administered concurrently with the 
vaccine at a dose of 1 mg/kg to reduce side effects.  
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Table I.1. Summary of vaccine reactions experienced by participating dogs. * denotes the 
administration of diphenhydramine concurrently with the vaccine 
DOG  FIRST INJECTION  BOOSTER INJECTION 
Lilly Marcum  Lethargic 72 hours  Lethargic 24 hours 
Kassie Reyes  Lethargic, soreness at injection 
site 24 hours  Lethargic 24 hours 
Bonnie Corse  Lethargic, soreness at injection 
site 24 hours 
Lethargic, soreness at injection 
site 24 hours 
Ruby 
Hasenstein  No change  Lethargic 24 hours 
Tess Pearce  No change  No change 
Koda Langston  Tachypnea and distress 24 hours  Removed from study 
Kaia Owen  No change  Edema and soreness at injection 
site 36 hours 
Branson Blount  No change  Lethargic and soreness at 
injection site 24 hours 
Azaria Acosta  No change  Edema and soreness at injection 
site 24 hours 
Penny Moquin  Lethargy 24 hours  *Lethargy and soreness at 
injection site 24 hours 
Lily Gassner  Lethargy and decreased appetite 
24 hours  *Lethargy 24 hours 
Mia Wanser 
Lethargy, stiff, painful movement 
and soreness at injection site for 
144 hours 
Removed from study 
Lena Mills  Lethargy and soreness at injection 
site 24 hours 
*Lethargy 24 hours, alopecia at 
injection site 
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APPENDIX J: GNRH ANTIBODY ELISA PROTOCOL - CANINE 
  The GnRH antibody ELISA protocol was developed using the technique of Elhay 
and coworkers (2007) with some modifications. This is an indirect ELISA that uses 
horseradish peroxidase (HRP;101223, Life Technologies Corporation, Carlsbad CA) as the 
enzyme-labeled detection antibody and the reagent ABTS (50-66-00, KPL Inc., 
Gaithersburg MD) as the colorimetric substrate that visualizes HRP. ABTS is a less 
sensitive substrate than others available and is therefore the ideal choice for this already-
sensitive ELISA; a more sensitive substrate choice would cause false positive results. A 
schematic summarizing this ELISA protocol can be seen in Figure J.1. To run three plates 
with five samples per plate, the time commitment on the first day of the protocol is 
approximately half an hour and the time commitment on the second day of the protocol is 
approximately five hours. 
  Human LH-RH, 1MG (71447-49-9, Sigma, St. Louis, MO) is utilized as the antigen 
in this ELISA; it is delivered in a powdered form and reconstituted in a 1 mg/mL solution . 
To reconstitute, add 1000 μL fresh distilled water total to the powder in increments no 
greater than 500 μL to prevent overflow. Briefly, add 500 μL water to the LH-RH vial, cap 
the vial and invert to mix, and pipette the solution into an empty centrifuge tube. Add 
another 500 μL water back to the vial, cap the vial and invert to mix, and pipette the 
resulting solution into the same centrifuge tube. This ensures all LH-RH sediments are 
reconstituted. Finally, aliquot LH-RH was into microcentrifuge tubes. To maintain coating 
of 5 μg/mL per well, as needed for the canine ELISA protocol, 50 μL LH-RH is needed per 109 
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96-well plate. An experienced assay operator can  reliably run three plates at once and 
therefore, 160 μL of LH-RH (extra to allot for pipetting error) is the standard aliquot. 
Reconstituted LH-RH remains stable for a approximately one month at -20°C. 
  Coating the plates is performed on Day 1 of the protocol. While reconstituted LH-
RH is thawing on ice, make sodium bicarbonate buffer, which is composed of sodium 
bicarbonate and distilled water, to dilute the LH-RH. To maintain coating of 5 μg/mL per 
well, 10 mL of sodium bicarbonate buffer is needed per plate. Measure the appropriate 
amount of sodium bicarbonate (Table J.1) into a beaker with a stir bar containing half the 
amount of desired water (Table J.1) and mix using a stirring plate. Once thoroughly mixed, 
read the pH of the buffer using a pH meter. The buffer must be at or close to 8.0, so HCl  or 
NaOH are added to adjust pH.  
If the pH meter has not been used recently, it should be calibrated using pre-made 
samples. When using the meter, the crystal must always remain wet, stored in a water-filled 
cap, and rinsed between substances with distilled water. Once the buffer is adjusted to 8.0, 
pour the contents of the beaker into a graduated cylinder and add distilled water to measure 
to the exact amount of water needed.  
  Measure the exact amount of sodium bicarbonate buffer needed and pour into a 
reservoir. For example, if three plates are being run, 30 mL of buffer is needed minus 150 
μL LH-RH, so 29, 850 μL buffer should be measured into the reservoir. Vortex 150 μL 
thawed LH-RH and then pipette into the reservoir. Mix the solution by pipetting the buffer 
up and down a few times with a multi-channel pipettor, then pipette 100 μL of the LH-RH 110 
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in the sodium bicarbonate buffer into each well. Finally, place a plastic cover over the plate, 
pressed around the edges for a strong seal, and refrigerate overnight. 
  On Day 2 of the protocol, perform the ELISA. To begin, make two buffers, the 
bovine serum abumin (BSA) dilution buffer and the phosphate d buffered saline with tween 
(TPBS) wash buffer.  For the BSA buffer, measure the appropriate amount of NaCl, 
NaH2PO4, and Na2HPO4 (Table J.2) into a beaker with a stir bar containing half the amount 
of desired water (Table J.2) and mix using a stirring plate. Once thoroughly mixed, read the 
pH of the buffer and adjust to 8.0. Next, measure BSA (Table J.2) and add to the beaker to 
mix. Pour the contents of the beaker into a graduated cylinder and add distilled water to 
measure to the exact amount of water needed. Store the BSA buffer in the refrigerator; it can 
be stored for use for approximately 2 weeks.  
  TPBS wash buffer stores for a long period of time and therefore, large quantities are 
made at once. To make the TPBS wash buffer, measure the appropriate amount of NaCl, 
NaH2PO4, and Na2HPO4 (Table J.3) into a 4000 mL flask with a stir bar containing half the 
amount of desired water (Table J.3) and mix using a stirring plate. Once thoroughly mixed, 
the pH of the buffer and adjust to 8.0. Next, add distilled water to the flask to measure to the 
exact amount of water needed. Finally, add Tween-20 to the flask (Table J.3) and mix on the 
stirring plate. TPBS is stored at room temperature with parafilm covering the flask opening. 
  The 96-well plate layout is depicted in Figure C.1. Briefly, 5 serum samples fit on 
one plate and each is diluted from a 1:8 - 1:1024 dilution. To perform the "dilution train," 
place dilution tubes in five rows of 8 on a tube rack and label according the serum sample. 
Pipette 700 μL of BSA dilution buffer into the first tube of each row; pipette 400 μL of BSA 111 
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dilution buffer into the remaining tubes. Next, pipette 100 μL of the thawed, vortexed serum 
sample into the first tube of each row (the tube with 700 μL of BSA dilution buffer in it). 
Vortex the tube and remove 400 μL from the first tube and place into the second tube. After 
mixing the contents of the second tube via aspiration with the pipette, remove 400 μL from 
the second tube and place into the third tube. Repeat this process until the end of the row is 
reached. After each dilution train is performed, there is 400 μL of diluted serum in each tube 
except for the very last tube, which will have 800 μL of diluted serum. The first tube is a 1:8 
dilution, the second a 1:16 dilution, and so on. 
  Next, calculate the positive and negative controls. The negative control is made at a 
1:8 dilution, 100 μL  in each well, and 8 wells per plate.In this study, negative control serum  
was collected from a spayed, unvaccinated female. To calculate, multiply the number of 
plates being run × 8 wells × 100 μL, and this equals amount of total solution needed for the 
negative control. Round this number up to allot for pipetting error, then divide by 8 (to 
account for the 1:8 dilution) to determine the amount of negative control serum needed. 
Subtract the amount of negative control serum needed from the total amount of solution 
calculated, and this equals the amount of BSA dilution buffer to add to the negative control 
serum. For an example of this calculation, see Figure J.3. 
  The positive control in this study was created by pooling positive-titer intact male 
dog serum samples obtained from a previous study (Donovan et al., 2012). The amount 
available was limited, and therefore, positive controls were calculated at a 1:27 dilution, 100 
μL  in each well, and 8 wells per plate. To calculate, multiply the number of plates being run 
× 8 wells × 100 μL, and this equals amount of total solution needed for the  positive control. 112 
 
 
101  
Round this number up to allot for pipetting error, then divide by 27 (to account for the 1:27 
dilution) to determine the amount of positive control serum needed. Subtract the amount of 
positive control serum needed from the total amount of solution calculated, and this equals 
the amount of BSA dilution buffer to add to the positive control serum. For an example of 
this calculation, see Figure J.4. 
  After all test serum samples are diluted and the controls are made, the plate is ready 
to be loaded with samples. Remove the coated plates from the refrigerator, allow to reach 
room temperature, and then tap-dry and rinse with TPBS. Briefly, the solution remaining in 
the plates was emptied into the sink and the plate was then vigorously slammed onto dry 
paper towels (tap-drying) until no more liquid was coming off onto the paper towels. The 
plate wells were then filled with TPBS, emptied into the sink, and then vigorously slammed 
onto paper towels until no more liquid was coming off. Vigorous slamming is necessary to 
remove all unbound material; any left behind will result in background and false positive 
results.  
Next, load the plate with controls and samples, 100 μL per well, following the layout 
of Figure J.2 with each sample being vortexed  a new pipette tip being used for every new 
sample. Cover the plate with adhesive film and  incubate for one hour at room temperature. 
  During the incubation, calculate the amount of HRP solution needed to add to the 
plates. The HRP solution is made at a 1:2000 dilution, 100 μL  in each well, and 96 wells 
per plate. To calculate, multiply the number of plates being run × 96 wells × 100 μL, and 
this equals amount of total solution needed for the HRP solution. Round this number up to 
allot for pipetting error, then divide by 2000 (to account for the 1:2000 dilution) to 113 
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determine the amount of HRP needed. Subtract the amount of HRP needed from the total 
amount of HRP solution calculated, and this equals the amount of BSA dilution buffer to 
add to the HRP. For an example of this calculation, see Figure J.5. 
  After the incubation period was over, empty the plate contents into the sink, tap-dry, 
rinse with TPBS, tap-dry, rinse and empty with TPBS three times, and tap-dry again. Mix 
the HRP solution in a well using a multichannel pipettor and add to the plate, 100 μL per 
well, cover with adhesive film, and incubate for one hour. 
  After this incubation  period is over, add ABTS to the plate and immediately read in 
a spectrophotometer (FLUOstar Omega, BMG Labtech Inc, San Francisco, CA). The 
spectrophotometer available for use is located in the Linus Pauling Science Center in Dr. 
Gerd Bobe's lab, so all materials needed must be moved to his laboratory before adding 
ABTS. Once incubation is over, empty the plate contents into the sink, tap-dry, rinse with 
TPBS, tap-dry, rinse and empty with TPBS three times, and tap-dry again. Next, put 11 mL 
of ABTS into a well using the Drummond pipette-aid. ABTS is light-sensitive, so it must be 
exposed to light for as short of a period as possible. Pipette ABTS quickly into the plate, 100 
μL per well, using a multichannel pipettor.  
  After ABTS is added, the colormetric reaction is almost immediate. Insert the plate 
immediately into the plate reader and read at 405 nm. Repeat readings immediately for up to 
7 minutes; a successful reading is defined as positive and negative control lanes having little 
variability between wells, duplicates having little variability between wells, and the positive 
control lane being around 1.3 - 1.5 OD. For an example of a successful plate, see Figure J.6.  
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Table J.1. Sodium bicarbonate buffer composition 
Distilled Water (mL)  Sodium Bicarbonate needed (g) 
100  .840 
50  .420 
35  .287 
25  .205 
10  .082 
5  .041 
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Table J.2. BSA dilution buffer composition 
Distilled Water  NaCl (g)  NaH2PO4 (g)  Na2HPO4 (g)  BSA (g) 
100 ml  .8167  .01698  .67  .5 
500 ml  4.0835  .084  3.35  2.5 
1 L  8.167  .1698  6.7  5 
5 L  40.835  .849  33.5  25 
10 L  81.670  1.698  67.00  50 
20 L  163.340  3.4  134.00  100 
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Table J.3. TPBS wash buffer composition 
Distilled Water  NaCl (g)  NaH2PO4 (g)  Na2HPO4 (g)  Tween (mL) 
100 ml  .08167  .01698  .67  .05 
1 L  8.167  .1698  6.7  5 
4 L  32.668  .6792  26.8  2 
5 L  40.835  .849  33.5  2.5 
10 L  81.670  1.698  67.00  5 
20 L  163.940  3.400  134.00  10 
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Figure J.1. GnRH antibody ELISA protocol summary 
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Figure J.2. GnRH antibody ELISA 96 well plate layout 
Neg = negative control, Pos = positive control, S = test sample 
  1  2  3  4  5  6  7  8  9  10  11  12 
A 
Neg 
1:8 
Pos 
1:27 
S1 
1:8 
S1 
1:8 
S2 
1:8 
S2 
1:8 
S3 
1:8 
S3 
1:8 
S4 
1:8 
S4 
1:8 
S5 
1:8 
S5 
1:8 
B 
Neg 
1:8 
Pos 
1:27 
S1 
1:16 
S1 
1:16 
S2 
1:16 
S2 
1:16 
S3 
1:16 
S3 
1:16 
S4 
1:16 
S4 
1:16 
S5 
1:16 
S5 
1:16 
C 
Neg 
1:8 
Pos 
1:27 
S1 
1:32 
S1 
1:32 
S2 
1:32 
S2 
1:32 
S3 
1:32 
S3 
1:32 
S4 
1:32 
S4 
1:32 
S5 
1:32 
S5 
1:32 
D 
Neg 
1:8 
Pos 
1:27 
S1 
1:64 
S1 
1:64 
S2 
1:64 
S2 
1:64 
S3 
1:64 
S3 
1:64 
S4 
1:64 
S4 
1:64 
S5 
1:64 
S5 
1:64 
E 
Neg 
1:8 
Pos 
1:27 
S1 
1:128 
S1 
1:128 
S2 
1:128 
S2 
1:128 
S3 
1:128 
S3 
1:128 
S4 
1:128 
S4 
1:128 
S5 
1:128 
S5 
1:128 
F 
Neg 
1:8 
Pos 
1:27 
S1 
1:256 
S1 
1:256 
S2 
1:256 
S2 
1:256 
S3 
1:256 
S3 
1:256 
S4 
1:256 
S4 
1:256 
S5 
1:256 
S5 
1:256 
G 
Neg 
1:8 
Pos 
1:27 
S1 
1:512 
S1 
1:512 
S2 
1:512 
S2 
1:512 
S3 
1:512 
S3 
1:512 
S4 
1:512 
S4 
1:512 
S5 
1:512 
S5 
1:512 
H 
Neg 
1:8 
Pos 
1:27 
S1 
1:1024 
S1 
1:1024 
S2 
1:1024 
S2 
1:1024 
S3 
1:1024 
S3 
1:1024 
S4 
1:1024 
S4 
1:1024 
S5 
1:1024 
S5 
1:1024 
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Figure J.3. GnRH antibody ELISA negative control solution calculation 
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Figure J.4. GnRH antibody ELISA positive control solution calculation 
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Figure J.5. GnRH antibody ELISA HRP solution calculation 
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Figure J.6. GnRH antibody ELISA successful plate reading. For layout, see Figure J.2. 
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APPENDIX K: ANALYSIS OF GNRH ANTIBODY ELISA RESULTS 
  The results of the GnRH antibody ELISA are reported as endpoint titers, which 
are the reciprocal of the highest dilution of serum that gives a reading above a cutoff 
(Frey et al. 1998). The cutoff is derived from the negative controls and are calculated by 
the equation Cutoff = x    + SDƒ, where x    is the mean of all negative control optical 
densities (ODs), SD is the standard deviation of all negative control ODs, and ƒ is a 
standard deviation multiplier (Frey et al. 1998). The standard deviation multiplier is 
derived from the chosen confidence level and number of negative controls used; see 
Table K.1 for the values of ƒ corresponding to confidence levels and negative controls. 
  To begin the conversion from raw OD to endpoint titer, first determine the cutoff. 
For this study, there were eight wells of negative control samples per plate and the chosen 
confidence level was 99%, so ƒ = 3.180. The mean and standard deviation of the negative 
controls were calculated, and the cutoff was then derived from these values. For an 
example calculation, see Figure K.1. 
   Next, compare samples to the cutoff. Because all samples are run in duplicate, 
average the ODs, then subtract the calculated cutoff value from the averaged OD. If the 
resulting number is positive, the sample is considered positive. If the resulting number is 
negative, the sample is considered negative. For visual clarity, positive values are 
highlighted. For an example of this calculation, see Figure K.2. 
  The final endpoint titer is expressed as the reciprocal of the greatest dilution that 
yielded a positive result. Therefore, using Figure K.2 as an example, the Week 4 titer 125 
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would be 32, the Week 6 titer would be 512, and so forth. However, these dilutions are 
not linear and therefore not normally distributed. For example, the titer difference 
between 8 and 16 is the same as the titer difference between 512 and 1024, but data 
analysis programs will not treat the titers as such. Therefore, titers have to undergo 
logarithmic transformation so titers can be represented linearly for statistical analysis, 
calculation of standard deviations, graphing, etc. In this study, 2-fold dilutions were used 
and therefore, titers were log-transformed to the base 2. See Table K.2 for the log-2 
transformations of the reciprocals of the serial dilutions. 
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Table K.1. Standard deviation multipliers (ƒ) (Frey et al. 1998) 
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Table K.2. Log-2 transformed  GnRH antibody titers 
Reciprocal of the 
Serial Dilution 
Log-2 
Transformation 
8  3 
16  4 
32  5 
64  6 
128  7 
256  8 
512  9 
1024  10 
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Figure K.1. Calculation of a cutoff 
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Figure K.2. Example calculation of sample ODs minus calculated cutoffs 
Averaged ODs: 
Dilution  Wk 0  Wk 4  Wk 6  Wk 8  Wk 10  Wk 12  Wk 16  Wk 20  Wk 24 
1:8  0.211  0.9505  1.5925  1.0955  1.142  1.6955  1.355  0.9525  0.459 
1:16  0.1895  0.71  1.6195  1.2355  1.153  1.61  1.254  0.679  0.404 
1:32  0.2025  0.492  1.35  1.2065  1.027  1.231  0.732  0.402  0.325 
1:64  0.186  0.3985  0.78125  1.131  0.783  1.0855  0.5885  0.304  0.248 
1:128  0.203  0.303  1.239  0.9745  0.5945  0.6595  0.376  0.235  0.2245 
1:256  0.1915  0.2895  1.1845  0.7875  0.4095  0.4595  0.31  0.186  0.186 
1:512  0.119  0.187  0.701  0.501  0.344  0.3045  0.216  0.169  0.1575 
1:1024  0.1115  0.129  0.4085  0.374  0.279  0.154  0.136  0.1435  0.1465 
 
Calculated cutoffs: 
  Wk 0-10:   0.408467 
  Wk 12-24:   0.34505 
 
Average ODs minus calculated cutoffs: 
Dilution  Wk 0  Wk 4  Wk 6  Wk 8  Wk 10  Wk 12  Wk 16  Wk 20  Wk 24 
1:8  -0.197  0.542  1.184  0.687  0.733  1.350  1.009  0.607  0.113 
1:16  -0.218  0.301  1.211  0.827  0.744  1.264  0.908  0.333  0.058 
1:32  -0.205  0.083  0.941  0.798  0.618  0.885  0.386  0.056  -0.020 
1:64  -0.222  -0.009  0.372  0.722  0.374  0.740  0.243  -0.041  -0.097 
1:128  -0.205  -0.105  0.830  0.566  0.186  0.314  0.030  -0.110  -0.120 
1:256  -0.216  -0.118  0.776  0.379  0.001  0.114  -0.035  -0.159  -0.159 
1:512  -0.289  -0.221  0.292  0.092  -0.064  -0.040  -0.129  -0.176  -0.187 
1:1024  -0.296  -0.279  0.000  -0.03  -0.129  -0.191  -0.209  -0.201  -0.198 
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APPENDIX L: LH-DETECT
® FOR CANINES ELISA PROTOCOL 
 
  LH-Detect
® for Canines (Repropharm, Nouzilly, France) is a sandwich-type ELISA 
that uses a scale of standards for quantitative results and is a more affordable alternative to 
measuring LH compared to a radioimmunoassay. Serum, plasma, or whole blood can be 
used in this assay. The assay was performed according to the manufacturer's instructions and 
for the contents of the kit, see Figure L.1.  
  Briefly, remove the ELISA plate, the dilution (DIL) substrate, and scale of  
standards (referred to as GAM in Figure L.1) from the kit. Thaw the plate at room 
temperature, thaw the DIL in tepid water, and thaw the scale of standards on ice. At this 
time, also thaw the test samples on ice. Each plate fits 40 samples; to see a plate layout 
design, see Figure L.2. 
  While thawing occurs, label forty centrifuge tubes with the test sample dog name 
and date of sampling.  Once the DIL is thawed, add 200 μL of DIL to each centrifuge tube. 
Vortex the thawed test sample and add 50 μL to the correctly labeled centrifuge tube. Repeat 
this for all 40 samples. Vortexthe centrifuge tube and  deposit100 μL of the diluted sample 
into the specified wells. Finally, vortex the scale of standards were individually and deposit 
into the specified wells. All samples and standards are deposited in duplicate. Cover the 
plate with an adhesive film and incubate at room temperature for one hour. During 
incubation, thaw the second antibody, AC2, from the kit in tepid water. 
  After the incubation period ends, rinse the plate five times with phosphate buffered 
saline with tween (TPBS) wash buffer (See appendix J, table J.4 for the wash buffer 131 
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composition), and tap-dry in between each rinse. Pour the thawed AC2 into a well and 
pipette100 μL into each well using a multichannel pipettor. Re-cover the plate with  
adhesive film and incubate at room temperature for another hour. During this second 
incubation, the enzyme-conjugated antibody, AC3, was thawed in tepid water. 
  After the second incubation, rinse the plate again with TPBS five times and tap-dry 
between each rinse. Pour thawed AC3  into a well and pipette100 μL into each well using a 
multichannel pipettor. Re-cover the plate with  adhesive film and incubate at room 
temperature for another hour. During this third incubation, thaw the colorimetric substrate 
(SUB) and  stop solution (STOP) in tepid water. For this study, the SUB solution was TMB, 
recommended by the manufacturer for a quantitative results, and STOP was a sulfuric acid 
solution.  
  Shortly before the third incubation ended, supplies need to be brought to the 
laboratory housing the spectrophotometer (FLUOstar Omega, BMG Labtech Inc, San 
Francisco, CA). After incubation, rinse the plate with TPBS five times and tap-dry between 
each rinse. Pour thawed TMB was then into a well and pipette 100 μL into each well using a 
multichannel pipettor. Insert the plate immediately into the spectrophotometer and read at 
650 nm repeatedly until the 8 ng/mL standard reaches 0.35 OD. Once this occurs, remove 
the plate and pipette 50 μL of STOP into each well using a multichannel pipettor. Then 
place the plate back into the spectrophotometer and read at 450nm repeatedly for 30 
minutes. A successful reading is defined as the scale of standards increasing in optical 
density as the concentrations increase  as well as duplicates having little variability between 
wells. For an example of a successful plate, see Figure L.3.  132 
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Figure L.1. Contents of LH-Detect
® for canines kit 
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Figure L.2. LH-Detect
® ELISA plate layout 
Columns 1 and 2 represent the scale of standards, S = test sample 
  1  2  3  4  5  6  7  8  9  10  11  12 
A 
0 
ng/mL 
0 
ng/mL  S1  S1  S9  S9  S17  S17  S25  S25  S33  S33 
B 
0.12 
ng/mL 
0.12 
ng/mL  S2  S2  S10  S10  S18  S18  S26  S26  S34  S34 
C 
0.25 
ng/mL 
0.25 
ng/mL  S3  S3  S11  S11  S19  S19  S27  S27  S35  S35 
D 
0.5 
ng/mL 
0.5 
ng/mL  S4  S4  S12  S12  S20  S20  S28  S28  S36  S36 
E 
1 
ng/mL 
1 
ng/mL  S5  S5  S13  S13  S21  S21  S29  S29  S37  S37 
F 
2 
ng/mL 
2 
ng/mL  S6  S6  S14  S14  S22  S22  S30  S30  S38  S38 
G 
4 
ng/mL 
4 
ng/mL  S7  S7  S15  S15  S23  S23  S31  S31  S39  S39 
H 
8 
ng/mL 
8 
ng/mL  S8  S8  S16  S16  S24  S24  S32  S32  S40  S40 
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Figure L.3. Successful LH-Detect
® plate reading. For layout, see figure L.2. 
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APPENDIX M: ANALYSIS OF LH-DETECT
® ELISA RESULTS 
  For this assay, optical density (OD) is converted into concentrations (ng/mL) 
based upon the manufacturer's provided scale of standards. This is typically achieved by 
developing a standard curve, plotting the OD of the standard (y axis) against the given 
concentration of the standard (x axis) and comparing test sample ODs to the curve to 
determine the concentration. However, the scale of standards for this assay does not 
increase linearly, so logarithmic transformation is needed to develop an accurate standard 
curve. 
  For this study, the development of the curve and consequent calculations to 
determine test sample concentrations were derived using an Excel® (Microsoft 
Corporation , Redmond WA) template developed by Dr. Katsumi Wakabayashi (2008). 
Briefly, average the ODs of each standard and subtract the OD of the 0 ng/mL (blank) 
standard from all other standards. If a standard OD does not increase accordingly with 
increasing concentration, remove it. The resulting values (ΔBlank) are then log 
transformed to the base e (ln(ΔBlank)). The given concentrations of the scale of standards 
are log-transformed to the base e and plotted against ln(ΔBlank) to develop the standard 
curve. Finally, add a 3rd order polynomial trendline to derive the equation of the line. An 
example of these calculations and the derived standard curve can be seen in Figure M.1. 
  To compare test samples to the curve, they also must be log-transformed . Briefly, 
subtract the OD of the blank from the OD of each sample, and these values are then log-
transformed to the base e. This resulting value (ln(ΔBlank)) is inserted into the equation 136 
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of the standard curve, giving the value Cal(ln). Take the inverse natural logarithm from 
Cal(ln), and this results in a calculated concentration of the test sample (CalCon). 
Because each sample was run in duplicate, the CalCon values of duplicate samples are 
averaged to determine the final concentration of the sample in ng/mL (FinCon). An 
example of this calculation process is seen in Figure M.2. 
 
References 
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Figure M.1. Development of a standard curve 
Scale of Standard 
Concentrations, 
ng/mL (Conc.) 
ln(Conc.)  OD  OD  Averaged 
ODs 
Averaged OD 
minus 
averaged OD 
of blank 
(ΔBlank) 
ln(ΔBlank) 
8  2.079442  0.745  0.748  0.7465  0.2655  -1.32614 
4  1.386294  0.648  0.63  0.639  0.158  -1.84516 
2  0.693147  0.57  0.584  0.577  0.096  -2.34341 
1  0  0.561  0.522  0.5415  0.0605  -2.80511 
0.25  -1.38629  0.516  0.514  0.515  0.034  -3.38139 
0.12  -2.12026  0.483  0.514  0.4985  0.0175  -4.04555 
Blank (0) 
 
0.465  0.497  0.481 
     
Plot ln(Conc.) (y axis) against ln(ΔBlank) (x axis). Add a polynomial trendline, order 3, 
to derive the equation of the line. 
 
 
 
 
 
 
   
y = -0.1975x3 - 1.6517x2 - 2.6917x + 0.9115 
R² = 0.9948 
-3 
-2 
-1 
0 
1 
2 
3 
-5  -4  -3  -2  -1  0 
Standard Curve 
Standard Curve 
Poly. (Standard Curve)  
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Figure M.2. Calculation of test samples from OD to ng/mL concentrations 
OD1  OD2  (ΔBlank)1  (ΔBlank)2  ln(ΔBlank)1  ln(ΔBlank)2  Cal(ln)1  Cal(ln)2  CalCon1  CalCon2  FinCon 
0.806  0.791  0.325  0.31  -1.123  -1.171  2.134  2.119  8.454  8.328  8.391 
0.765  0.744  0.284  0.263  -1.258  -1.335  2.080  2.034  8.008  7.650  7.829 
0.747  0.722  0.266  0.241  -1.324  -1.422  2.042  1.970  7.707  7.173  7.440 
0.749  0.741  0.268  0.26  -1.316  -1.347  2.046  2.027  7.743  7.591  7.667 
0.702  0.685  0.221  0.204  -1.509  -1.589  1.894  1.813  6.647  6.134  6.391 
0.789  0.774  0.308  0.293  -1.177  -1.227  2.117  2.096  8.308  8.134  8.221 
0.74  0.729  0.259  0.248  -1.350  -1.394  2.024  1.99  7.571  7.336  7.453 
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Appendix N: LH Concentration Comparison with Continent Bitches 
  Venous blood samples were taken from twenty-seven medium-sized (25-49 
pounds of body weight) and large-sized (50-100 pounds) healthy, continent 
ovariectomized bitches. These samples were used to compare LH concentrations to the 
sixteen incontinent bitches previously sampled (see Chapter III). All continent bitches 
were ovariectomized (OE) at least one year prior to sampling.  
  LH concentration comparisons were made between and within groups with regard 
to continence, size and age at OE using PROC TTEST in SAS (Version 9.2, SAS 
Institute Inc., Cary, NC). Results are summarized in Table N.1. In general, incontinent 
bitches had lower LH concentrations compared to continent bitches (p=0.04), consistent 
with findings reported previously by Reichler et al. (2005).  However, when the size of 
bitch was included in this comparison, LH concentrations were only significantly 
different between medium-sized bitches (p=0.02)  but not between large-sized bitches 
(p=0.79).  It is important to note that in general, medium-sized bitches had higher LH 
concentrations than large-sized bitches.  
  Overall, age at ovariectomy did not significantly affect LH concentrations.  
However, there was a trend for incontinent bitches ovariectomized under one year of age 
to have LH concentrations lower than continent bitches ovariectomized at a similar time 
(p=0.06) and for LH concentrations to be higher than in incontinent bitches who were 
ovariectomized over one year of age (p=0.07). 140 
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These findings support our hypotheses that 1) the development of incontinence in 
ovariectomized females is related to significantly lower LH concentrations; and 2) early 
age ovariectomy increases LH concentrations compared to older age ovariectomy. 
 
References 
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incontinence. Theriogenology 63, 2164-2180. 
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Table N.1. LH concentration comparisons between continent and incontinent 
ovariectomized bitches. 
VARIABLE  N 
MEAN LH 
CONCENTRATION 
(ng/mL) 
SEM  P 
Continent bitches  27  7.85  1.05 
0.04  Incontinent bitches  16  4.78  0.51 
SIZE 
Medium bitches  23  8.56  1.07  0.004 
Large bitches  20  4.56  0.69 
         
Medium continent bitches  15  10.34  1.40 
0.02  Medium incontinent bitches  8  5.22  0.72 
         
Large continent bitches  12  4.71  1.07 
0.79  Large incontinent bitches  8  4.32  0.73 
         
Medium continent bitches  15  10.34  1.40  0.005  Large continent bitches  12  4.71  1.07 
         
Medium incontinent bitches  8  5.22  0.72  0.39  Large incontinent bitches  8  4.32  0.73 
TIME OF OVARIECTOMY 
Bitches ovariectomized  ≤ 1 yr  30  7.12  0.90  0.37  Bitches ovariectomized  > 1 yr  13  5.72  1.12 
         
Continent bitches ovariectomized  ≤ 1 yr  17  8.57  1.47  0.06 
Incontinent bitches ovariectomized  ≤ 1 yr  13  5.22  0.54 
         
Continent bitches ovariectomized  > 1 yr  10  6.59  1.34  0.17 
Incontinent bitches ovariectomized  > 1 yr  3  2.86  0.71 
         
Continent bitches ovariectomized  ≤ 1 yr  17  8.57  1.47 
0.37  Continent bitches ovariectomized  > 1 yr  10  6.59  1.34 
         
Incontinent bitches ovariectomized  ≤ 1 yr  13  5.22  0.54  0.07  Incontinent bitches ovariectomized  > 1 yr  3  2.86  0.71 
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APPENDIX O: PUBLICATIONS, ABSTRACTS, AND POSTERS 
Appendix O.1. Summary 
Throughout my graduate career, I have been privileged to be able to collaborate 
with other researchers as well as present my research at regional, national, and 
international conferences. 
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Appendix O.2. Samylov, A., Cox, N., Cochran, A., Wolfe, K., Donovan, C., Kutzler, M., 
Petrenko, V., Baker, H., Samoylova, T. (2012). Generation and characterization of phage-
GnRH chemical conjugates for potential use in cat and dog immunocontraception. 
Reproduction in Domestic Animals 47(6), 406-411. 
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Appendix O.3. Presented at the 2013 Annual Conference for the Society for 
Theriogenology (SFT; Louisville, KY) 
 
GnRH Immunization for the Treatment of Urinary Incontinence in Spayed Bitches 
C.E. Donovan
1, J.M. Gordon
2, M.A. Kutzler
1 
1Department of Animal and Rangeland Sciences, Oregon State University, Corvallis, OR 
2College of Veterinary Medicine, Oregon State University, Corvallis, OR 
INTRODUCTION. Because urinary incontinence is common in spayed bitches (4.9-
20%) [1-2], it has been postulated that permanently elevated gonadotropin concentrations 
as a result of ovariectomy may contribute to the development of urinary incontinence [3]. 
Therefore, the purpose of this study was to determine if a gonadotropin releasing 
hormone (GnRH) vaccine, labeled for the management of benign prostatic hyperplasia in 
intact male dogs, would also be effective for the treatment of urinary incontinence in 
spayed bitches. It was hypothesized that spayed incontinent bitches immunized against 
GnRH would develop antibodies that would prevent gonadotropin elevation, resulting in 
a return to continence. 
METHODS. Nine privately-owned bitches diagnosed with urinary incontinence 
following ovariohysterectomy were used for this study. All bitches had been receiving 
daily oral phenylpropanolamine (PPA; Proin
®, PRN Pharmacal, Pensacola, FL) to control 
incontinence prior to the start of the study. Six bitches received two subcutaneous 
injections of Canine Gonadotropin Releasing Factor Immunotherapeutic
 vaccine (Pfizer 
Animal Health, Exton, PA) at 4 week intervals, and three bitches received two placebo 
injections at 4 week intervals. Venous blood samples were collected pre-vaccination 
(week 0) and weeks 4, 6, 8, 10, 12, 16, 20, and 24. Vaccinated bitches discontinued PPA 
use two weeks after receiving the second injection; control bitches remained on PPA for 
the duration of the study. Owners recorded all episodes of incontinence. Serum GnRH 
antibody titers were determined by an enzyme linked immunosorbent assay and antibody 
titers were analyzed using Fisher's exact test (GraphPad QuickCalcs Software, La Jolla, 
CA). Significance was defined as p<0.05. 
RESULTS. Side effects of the vaccine included soreness at the injection site (n=1), 
swelling at the injection site (n=1), lameness (n=1), and tachypnea (n=1, dog removed 
from the study). All side-effects resolved without treatment within 24 hours. All dogs 
were seronegative for GnRH antibodies at week 0 and control dogs remained 
seronegative for the duration of the study. Vaccinated dogs developed a GnRH antibody 
titer that was significant compared to control dogs at weeks 4-16 (p=0.02). Of the five 
vaccinated dogs that completed the study, two dogs remained continent for 112.5±23.3 
days after PPA was discontinued, while three dogs became incontinent 3.6±2.1 days after 
PPA was discontinued despite having elevated GnRH antibody titers. 
CONCLUSION. The pathophysiology of urinary incontinence following ovariectomy is 
not well understood. The results of this study show that reducing gonadotropin 
concentrations by GnRH immunization may be necessary but not sufficient to restore 
continence in all bitches. Plasma luteinizing hormone measurements are currently being 
performed to determine whether GnRH immunization vaccine effectively decreases 
gonadotropin concentrations. 150 
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Appendix O.4. Presented at the 2012 Northwest Reproductive Sciences Symposium  
(NWRSS; Beaverton, OR) and the 2012 International Symposium on Canine and Feline 
Reproduction (ISCFR; Whistler, British Columbia, Canada) 
 
Endocrine Responses Following Gonadotropin Releasing Hormone (GnRH) 
Immunization in Intact Male Dogs 
 
Caitlin Donovan,
1 Timothy Hazzard,
1 Katherine Peed,
2 Steve Lamb,
3 Michelle Kutzler
1 
1Dept. of Animal Sciences., 
2College of Veterinary Medicine, Oregon State University, 
Corvallis, OR 97331, USA 
3Animal Health Diagnostic Laboratory, Cornell University, Ithaca, NY 14853, USA 
donovaca@onid.orst.edu 
 
INTRODUCTION. GnRH is responsible for the release of luteinizing hormone (LH) 
and follicle stimulating hormone (FSH) from the pituitary, which regulates reproductive 
steroid hormone synthesis. When vaccinated against GnRH, endogenous GnRH will be 
prevented from binding to its receptor in the pituitary, halting LH and FSH production. 
As a result, steroid hormones will not be synthesized. The objective of this study was to 
measure the endocrine responses to GnRH immunization in intact male dogs. Based upon 
the manufacturer’s label, we hypothesized that vaccinating against GnRH would elicit a 
GnRH antibody titer and decrease LH and testosterone concentrations in intact male dogs 
for six months. 
METHODS. Four privately-owned intact male dogs were used for this study. All were 
vaccinated with Canine Gonadotropin Releasing Factor Immunotheraputic® (Pfizer 
Animal Health, Exton PA) and boostered again four weeks later. Venous blood samples 
were collected at 0, 4, 12, and 20 weeks. Sera were separated, aliquoted, and frozen at -
20°C until analyzed. 
GnRH antibody titers were determined using an enzyme-linked immunosorbent assay 
(ELISA) using 1 µg/mL LH-RH as the antigen (71447-49-9, Sigma, St. Louis, MO, 
USA). LH samples were run in duplicate using a canine-specific ELISA (LH-Detect® for 
canines, ReproPharm, Nouzilly, France) and performed according to the manufacturer’s 
instructions. The sensitivity of the assay was 0.01 ng/mL and a value greater than 0.80 
ng/mL was determined to be a positive result. Testosterone concentrations were 
determined using a double antibody radioimmunoassay (Diagnostic Products 
Corporation, Los Angeles, CA). The detection limit of the assay was 0.04 ng/mL. 
Mean±SEM were determined for LH concentrations and compared between animals at 
the four time points using ANOVA with Bonferroni corrections. Mean±SD were 
determined for testosterone and GnRH antibody concentrations and compared between 
animals using ANOVA with Bonferroni corrections. Analysis was performed using Stata 
statistical software (Version 12; StataCorp. 2011, College Station, TX). Significance was 
defined as p<0.05. 
RESULTS. GnRH titers peaked 12 weeks following initial vaccination, which differed 
significantly from weeks 0 and 20 (Figure 1). Although LH and testosterone 152 
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concentrations appeared to lower at week 4 and week 12, respectively, these changes 
were not significant. 
DISCUSSION. GnRH immunization is an ideal candidate for nonsurgical contraception 
in dogs and cats because a single product should be effective in both males and females. 
However, GnRH is a weak immunogen and must be coupled to a large protein and 
combined with an adjuvant to enhance its antigenicity (1). The vaccine used in the 
current study was prepared commercially and our laboratory has previously used this 
vaccine to suppress estrus in female horses (2). It is not clear why these four male dogs 
responded weakly to vaccination.  However, using a different GnRH vaccine construct, 
Levy and coworkers (2004) reported that one-third of the male cats vaccinated against 
GnRH had a partial response with low positive GnRH antibody titers accompanied by 
equivocal serum testosterone concentrations (3). The small sample size in the current 
study is a limitation. Although assuming the differences observed in this study would be 
similar in a large population, 19 dogs would have needed to be studied to demonstrate 
significance.  
REFERENCES. 
(1) Sabeur K, Ball BA, Nett TM, Ball HH, Liu IKM. Effect of GnRH conjugated to 
pokeweed antiviral protein on reproductive function in adult male dogs. 
Reproduction. 2003 Jun;125(6):801-6. 
(2) Shaundra Epperson, Andrew Schmidt, Jo-Anne Le Mieux,
 et al. Effects of a 200-µg 
dose canine gonadotropin releasing hormone vaccination on mares. Proceedings for 
the Society for Theriogenology 2011 [abstract]. 
(3) Levy JK, Miller LA, Crawford PC, et al. GnRH immunocontraception in male cats. 
Theriogenology 2004;62:1116-1130. 
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Figure 1. Serum 
GnRH antibody 
titer as compared 
to testosterone and 
LH concentration 
(ng/mL) at weeks 
0, 4, 12, and 20 of 
four intact male 
dogs vaccinated 
with Canine 
Gonadotropin 
Releasing Factor 
Immunotheraputic
®. 
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Appendix O.5. 2012 NWRSS and 2012 ISCFR Poster 
 
 
 